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DESIGN AND SYNTHESIS OF NIR BODIPY DYES: APPLICATION FOR 
IN VIVO FLUORESCENCE IMAGING AND PHOTODYNAMIC THERAPY 
SAMUEL G. AWUAH 
2012 
 
Photodynamic therapy (PDT) and fluorescence imaging are non-invasive 
modalities for disease treatment and diagnosis respectively. Both modalities 
require the use of a dye (light harvesting material) and light or source of 
excitation. In the case of PDT a sensitizer is needed while a fluorophore is 
used in the case of fluorescence imaging. PDT in addition to a sensitizer 
and light thrives on oxygen to generate a key cytotoxic species known as 
singlet oxygen. PDT has shown promise in the clinic for the treatment of 
surface cancers and age-macular degeneration. Fluorescence imaging on 
the other hand has a long history for in vitro use but a growing interest for in 
vivo preclinical and clinical use for diagnosis, particularly in malignancies, 
angiography and neurobiology. Fluorescence imaging due to its sensitivity, 
relatively low cost and less toxicity makes it reliable. The need to improve 
PDT and imaging heavily relies on the effectiveness of the sensitizer or 
imaging probe/fluorophore. Near infra-red (NIR) sensitizer/probes with a 
potential to target specific sites of interest could change the paradigm in the 
non-invasive modalities. 
xxi 
 
In this dissertation, the design and synthesis of NIR BODIPY for use as 
photosensitizers and fluorescent probes was explored. We followed a 
synthetic strategy of incorporating heavy atoms in the BODIPY 
chromophore to obtain effective singlet oxygen generating BODIPY without 
compromising on their optical and photophysical properties with an added 
advantage of red-shifting to the NIR region. We further developed a robust 
but versatile strategy for building fluorescent molecular probes spanning the 
entire therapeutic window with potential for optical imaging. We then 
explored the capacity to functionalize these NIR dyes for potential targeting 
to vectors such as peptides, antibodies, etc. We also investigated the ability 
of representative dyes to induce photodynamic response and to serve as 
optical contrast agents.  
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Chapter 1  
General Introduction 
 
1.0. Introduction 
An enhanced clinical approach of disease diagnostics and treatment 
is of great interest due to its implication for healthy living. The search for 
novel non-invasive regimen/agents using tissue penetrable light (600 – 900 
nm) to improve disease prognosis and therapy is expanding among the 
scientific (clinical and preclinical) community due to its advantages of 
reduced toxicity by avoiding non-ionized species, relatively low cost and 
real time monitoring. The development of fluorescent probes for optical 
imaging and photosensitizers (PSs) originating from organic, inorganic and 
material science (especially nanomaterials) has been explored to produce 
diverse probes for various outcomes. In general, near infra-red (NIR) 
fluorescent probes and PSs for photodynamic diagnosis and therapy 
(PDD/PDT) respectively, are more effective than visible ones in the clinic 
due to deeper tissue penetration due to reduced absorption by cells/tissues 
and water, light scattering and autofluorescence.1, 2  
Currently, indocyanine green (ICG) as a fluorescent probe and a few 
PSs such as Photofrin, Visudyne, Foscan are used in the clinic. However, 
since those are not ideal for optical imaging or PDT, better probes/PSs 
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should be developed. Organic based dyes are relatively cheap, offer 
flexibility in tuning properties and show good biocompatibility. Frequently 
used dyes have been cyanines, squarines, porphyrins and boron 
dipyrromethene (BODIPY).  BODIPY is noted for high photostability, unique 
optical properties evidenced in sharp absorption and emission bands, high 
extinction coefficient and high fluorescence quantum yields as well as 
flexible synthesis and tunability. The central theme of my dissertation is 
focused on the development of NIR BODIPY structural variants for 
fluorescence imaging and PDT. The work: 1) developed NIR PSs from the 
low triplet state BODIPY via the heavy atom effect. 2) established a robust 
but versatile synthetic platform for fluorescent probes across the NIR 
therapeutic window (650 – 800 nm), and 3) developed functionalization 
strategies and dual functioning NIR BODIPY agent for PDT and 
fluorescence imaging. 
1.1. PDT  
The operation of PDT follows a tripartite modality involving light, PS 
and oxygen. A PS is administered and then the treatment site (e.g. tumor) 
is subjected to light irradiation to generate reactive oxygen species, 
especially singlet oxygen from oxygen, to damage target diseases. When a 
PS is irradiated, it is converted to the triplet state via intersystem crossing 
from the singlet state (Fig. 3).3 In what is known as the type II process, the 
triplet state PS transfers its energy to molecular oxygen to produce singlet 
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oxygen. In a type I process, a chemical reaction of the excited PS with a 
substrate occurs, initiating an electron or proton transfer leading to the 
formation of radicals which react with molecular oxygen to produce reactive 
oxygen species such as superoxide, hydrogen peroxide, and hydroxyl ion.4 
1.1.1. Light 
Optical technology has aided the groundbreaking evolution of the 
use of light in PDT from the use of sunlight to very sophisticated light 
sources and light delivery tools.5-7 Light for PDT is generally classified into 
laser and non-laser light sources. The effectiveness of lasers is higher than 
the other light sources offering advantages such as delivering high intensity 
with monochromaticity, no thermal effect, and easy adaptability with fiber 
optic delivery tools. Attenuation of incident light by biological tissue requires 
relatively high fluence rates or light doses for the treatment of bulky targets. 
The property of monochromaticity of lasers makes the dosimetry relatively 
more accurate than non-monochromatic light at least at the surface of the 
target tissue. In a classic PDT example, the FDA approved Photofrin and 
Visudyne work in combination with laser irradiation (630 and 689 nm, 
respectively). Diode lasers have become more popular in the PDT 
community due to their comparatively cheap but effective application. 
Alternatively, non-coherent light sources offer some advantages over lasers 
such as relatively low cost, ability to excite a wide range of spectra, 
compact size, easier handling, and less regulation. In instances where less 
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accurate dosimetric control is acceptable like dermatologic diseases, non-
coherent light sources are advantageous. The use of a narrow banded 
fluorescence light source (BLU-U, 400-450 nm) with absorption in the UV-
visible region has been used for the treatment of acne keratosis with 
Levulan. Another type of non-coherent light source available for preclinical 
application is the Lumacare, where special fibers are used to make 
narrow band outputs covering a wide range of spectrum. Recently, the 
portable, non-coherent but adjustable light emitting diodes (LEDs) have 
become readily available for PDT application.  The availability of good 
quality light, high power, low cost, and desirable delivery fibers has in part 
popularized PDT.1 
1.1.2. Singlet Oxygen, 1O2 (1∆g) 
Among reactive oxygen species (ROS), O2 (1∆g) proved to be the 
main cytotoxic agent of PDT to cause biological effects.3, 8-11 The quenching 
of the lowest electronically excited singlet (S1) and triplet (T1) states of 
substances with the possibility of transferred energy higher than 158 kJ/mol 
produces electronically excited two singlet oxygen states [1∑+g (158 kJ/mol) 
and 1∆g (94 kJ/mol)] above the triplet state oxygen.12, 13 The metastable but 
reactive O2 (1∆g) can be generated by the deactivation of O2 (1∑+g) through 
electronic and vibrational energy transfer.12, 13 Moreover, the longer lifetime 
of T1 than S1, supports that singlet oxygen (1∆g) is generated by energy 
transfer from T1 to triplet oxygen (Fig. 3). In assessing the biological effects 
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of singlet oxygen in PDT, three factors come into play. First, the 
concentration of oxygen and the source of singlet oxygen impact the 
capacity of singlet oxygen generation and consequently biological activity. 
The concentration of oxygen at atmospheric pressure in aqueous and 
organic media are different: for example, 0.27 mM (water) vs 2.40 (CHCl3), 
respectively.14 This affects the oxygen distribution at the tissue level. For a 
solid tumors known for its hypoxic property15 a reduction of oxygen 
concentration from 5 % to 1 %, results in 50 % decrease in PDT activity.9 
Second, the lifetime of singlet oxygen is short in aqueous media and thus 
its diffusion is limited to a short distance (10-300 nm).16-18 Singlet oxygen 
generated in a cell can only damage the cell conferring some degree of 
selectivity for PDT in targeted cells over normal cells. Third, singlet oxygen 
quantum yield (Ф∆) which is the quantitative expression of a PS’s potential 
to generate singlet oxygen19, 20 has been a useful characteristic in the 
assessment of PS efficacy in PDT, at least in solutions and in mono-layer 
cell culture models. A more useful term to predict PS efficiency may be 
“phototoxic power (PP)” where PP = Ф∆ ⨉ , accounting for singlet oxygen 
quantum yield and extinction coefficient of the PS1 for in vivo systems 
where light will be one of the limiting factors due to tissue attenuation. 
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1.1.3. PSs  
Over the past century, PSs evolved in terms of its chemical and 
photophysical properties and biological applications.  A PS is a dye that 
generates ROS for cellular/tissue damage after light irradiation. In 1903 a 
report by Jesionek and Von Tappeiner on the effect of the topical treatment 
of tumors with eosin exposed to white light marked one of the notable 
advances in photodynamic events (Fig. 3).21, 22 Photodynamic activity was 
extended by Polycarp in 1924 by using porphyrins to treat tumors.23  The 
rise of photodynamic activity received a major boost in 1960 when Richard 
Lipson and co-workers developed the “Haematoporphyrin derivative” (HPD) 
after the observation of fluorescence upon localization in tumors.24-28 In fact, 
a number of mouse model experiments buttressed the localization of 
haematoporphyrin and its analogues in tumors.29 Dougherty and his 
colleagues took PDT a step further by treating mammary tumors in vivo with 
HPD and red light.30 Subsequently, Kelly and Snell examined the first 
human treatment with HPD for bladder cancer.31, 32 Successful preclinical 
and clinical trials of HPD led to the approval of its purified form under the 
trade name Photofrin for PDT treatment of Barrett’s oesophagus, cervical 
cancer, endobroncheal cancer, oesaphageal cancer, gastric cancer and 
papillary bladder cancer in a number of countries.33 
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Figure 1. Milestones of PS development 
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1.2. Fluorescence Imaging 
In biological research fluorescence imaging proved useful in vitro 
and in vivo preclinical and clinical applications. Optical imaging generally 
offers high sensitivity and frame rate, low cost and portability, lack of 
radiation exposure and an ability to multiplex several colors 
simultaneously.34 
The sensitivity of fluorescence imaging in molecular biology, in vivo 
and clinical diagnostics accompanied with other numerous advantages has 
attracted great research attention. Fluorescent probes have been used to 
detect and quantify total DNA, RNA and protein. Using multicolor 
fluorescence detection, a time and cost effective strategy could be 
employed to resolve multiple targets. Fluorescent labeled biomolecules 
tend to be relatively stable in comparison to their radioisotope labeled 
counterparts. In addition, fluorophores are easier to transport and dispose, 
influencing their low cost. In vivo fluorescence imaging has been useful for 
cancer diagnostics (early stage), tumor boundary identification, assessment 
and visualization of blood and lymph vessels, fluorescence guided tumor 
resection etc. It is noteworthy that fluorescent probes can be characterized 
on the property of their brightness (BT=ε x Φf; where ε: extinction coefficient, 
Φf: fluorescence quantum yield), which is dependent on its excitation 
coefficient and quantum yield of fluorescence.  
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Fluorochromes such as cyanines, rhodamine, fluorescein, BODIPY, 
and etc. (Fig. 4) have been used as imaging probes and their improved 
versions have been developed. In current clinical practice, indocyanine 
green and fluorescein are the only two fluorescent probes approved by the 
Food and Drug Administration (FDA) for retinal angiography.35 
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9
λmax abs 465 - 490 nm
λmax emiss 520 - 530 nm
Fluorescite
ICG
10
 
Figure 2. FDA approved fluorescent contrast agents  
1.3. Molecular Electronic Processes 
Organic molecules are excited upon light absorption (light: ultraviolet, 
visible or near infra-red). The excitation involves electron transfer from the 
highest occupied molecular orbital (HOMO), which is low in energy to the 
lowest unoccupied molecular orbital (LUMO), which is high in energy. 
Singlet states and triplet states are the two formal excited electronic states. 
In the singlet state electron spins are paired even in the presence of a  mild 
magnetic field while in the triplet state the unpaired electron spins interact 
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with magnetic field to produce three quantized states.36 In a simplified 
model (Fig. 3), the absorption of organic molecules causes excitation to 
singlet states of varying vibrational energy levels. The electron may fall to 
lower vibrational energy levels in internal conversion (10-12 s) or fall to the 
ground state, emitting fluorescence.37 Spin conversion to the triplet state 
may also occur from molecules in the singlet state, the conversion is known 
as intersystem crossing with a general emission as phosphorescence. It is 
important to mention that intersystem crossing efficiency is greatly 
facilitated by heavy atoms such as I, and Br. The heavy atom effect induces 
spin orbit coupling enhancing phosphorescence quantum yields. 
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Figure 3. Simplified energy state diagram 
 
1.4. NIR organic PSs and fluorophores 
NIR materials are categorized as inorganic and organic, based on 
their composition. Organic NIR materials include extended π-conjugated 
chromophores, donor-acceptor type chromophores, some metal complexes 
as well as ionic dyes. NIR organic based matter has wide applications from 
its use as heat absorbers or optical filters in electronics, laser printers and 
charge generation materials38, information storage materials in optical 
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disks39, dye sensitized solar cells and medical applications such as PDT.40 
PSs or fluorochromes absorbing in the NIR region reaches deeper tissues 
(>500 µm to cm)41 for therapy and diagnosis respectively. Water, 
hemoglobin and deoxyhemoglobin have low extinction coefficients in the 
“so called” therapeutic window (650 – 900 nm), thus absorption by these 
tissue components is minimum.  In addition, in this therapeutic window 
autofluorescence is reduced and thus background signal is weak.  
In general, the molecular design of NIR organic materials is based 
on tuning the band gap (HOMO – LUMO gap) to low levels.40 In achieving 
this, strategies such as extending conjugation, incorporating donor-acceptor 
charge transfer elements, alternating bond length and at times the use of 
heavy atoms may be considered. Typical examples can be seen in 
chromophores like the polyenes with extended conjugation and polymethine 
units with terminal carbons which bear an electron donating group and the 
other end bears an acceptor group like the merocyanines, cyanines and 
hemicyanines. Other polymethines like the highly photostable BODIPY 
possess a rigidified core with excellent optical properties. Rhodamines with 
extended conjugation or replacement of O with Si atoms have been 
developed with fair photostability for bio-imaging. The naturally occurring 
bacteriochlorophyl-a with NIR absorption between700 – 800 nm has been 
useful in PDT and tumor imaging.42 The use of synthetic methods to make 
stable derivatives has attracted a lot of research interest.  
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Figure 4.  Structures of NIR dyes  
The use of donor - acceptor systems in an effort to tune the energy 
gap of organic substances were remarkable to obtain NIR absorption and 
emission. Organic materials were designed with electron donor and 
acceptor moieties linked with either a conjugated (π) or non-conjugated (σ) 
spacer referred to as D-π-A and D-σ-A respectively. Classic examples were 
the covalently linked tetrathiafulvalene (TTF) with tetracyano-p-
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quinodimethane (TCNQ) and the π-conjugation of TTF with dipyrido [3,2-
a:2,3-c]phenazine (Fig. 5).43, 44  
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Figure 5. Donor-acceptor system based on TTF with an acceptor  
 
1.5. Chemical Strategies for NIR BODIPY Dyes 
The quest for NIR BODIPY dyes has attracted great research 
interest over the years. The progress in building BODIPY dyes with 
excitability >700 nm is still nascent. The high photostability of the BODIPY 
chromophore is worthwhile to invest in it for NIR property returns. Currently, 
among the BODIPY dyes used for PDT and in vivo imaging, none absorbs 
beyond 700 nm. In an attempt to overcome this hurdle several approaches 
were be used to attain bathochromic shifts (Fig. 6). 1) Aryl substitution at 
the 1, 3, 5 and 7-positions of the BODIPY framework impart red-shift.45, 46 2) 
Using Heck-type (21) reactions, vinylation at the 2,6-positions with 
15 
 
respective acrylate moieties induced red shifts by about 20–30 nm with 
monosubstitution and 50–60 nm with di-substitution.47 Ethynylaryl 
substitution at the 3,5-positions of the BODIPY framework offers an 
appealing approach for red shifting. Using arylacetylene via the 
Sonogashira reaction (24) with its halogen-substituted BODIPY coupling 
partner made it possible to achieving longer wavelengths.48, 49 3) The 
Liebeskind–Srogl coupling with boronic acids or tin-based compounds50 as 
well as nucleophilic substitution of halogen-substituted BODIPY at the 3,5-
positions with conjugated groups did also induce a red shift.51, 52 4) A 
common route used to obtain long-wavelength BODIPY PSs is styryl 
substitution via Knoevanegel condensation (22). The versatile nature of 
styryl substitution produced moderate yields and was achieved in a 
stepwise fashion from monosubstitution to tetrasubstitution with an 
appropriate red-shift.53 Akkaya et. al. offered a sterling observation with 
insight of the acidity of methyl protons in a tetramethyl-BODIPY, indicating 
electron densities in the order 2,6 & 1,7 ~ 3,5 (18, Fig. 6).53 The methyl 
groups in positions 1 and 7 may be similar in acidity to those of 3, 5 methyl 
groups. 5) The strategy imploring extended conjugation by ring fusion is a 
smart approach for long wavelength BODIPY dyes. An example is the 
benzo-fusion following the retro-Diels– Alder reaction of norbornane-derived 
pyrroles executed by Ono and co workers.54-57 A method by Hao et al.58 
was developed for functionalized asymmetric benzo-fused BODIPY 6) 
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Heteroaryl ring fusion (23) to the BODIPY core in addition to extending 
conjugation imparted rigidity and planarity to the chromophore. Our 
research group including this dissertation and Suzuki et. al. demonstrated 
the use of the heteroaryl ring fusion approach to obtain  NIR absorbing and 
emitting dyes with excellent optical properties.59, 60 7) The aza-BODIPY (20) 
is a unique class that benefits from the replacement of the meso-carbon 
with a N atom of the BODIPY core. The lone pair electrons on the nitrogen 
atom engineer a narrow HOMO–LUMO gap by interfering with orbital 
framework of the pyrroles, hence, the bathochromic shift.40 The aza-
BODIPY analogues, ADPM06, in PDT have shown great promise with their 
far-red absorption being a strong selling point. Even though significant 
improvement was made, it did not address the problems of 
functionalization, water-solubility, NIR BODIPY PS or diagnostic agents. 
Those are indeed challenges that need to be surmounted. 
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Figure 6. Chemical modification strategies for long-wavelength BODIPY 
dyes 
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1.6. Thesis Objective and Outline 
Although significant works have been done to develop NIR BODIPY 
dyes, few have been successful for bio-imaging and PDT applications with 
excitability > 700 nm. A difficulty in functionalizing NIR organic dyes poses 
a challenge for biological applications. In this work I developed NIR 
BODIPY dyes absorbing >700 nm for potential use as PDT agents and in 
vivo fluorescence imaging probes. 
In Chapter 2, since the BODIPY chromophore is noted for low triplet 
states, fused BODIPY chromophores with extended conjugation were 
developed and the incorporation of heavy atoms produced NIR singlet 
oxygen generating BODIPY dyes. Photophysical characterization was 
carried out accordingly to assess the potential of these new dyes as PSs. 
Chapter 3, focused on the development of a robust synthetic strategy 
to generate NIR BODIPY fluorophores. Taking into account 
functionalization, incorporating functional groups at the meso position was 
explored. The challenges faced necessitated the building of a scaffold 
which is referred to as ‘versatile BODIPY intermediate’. The intermediate 
which is technically an alkyl halide serves as a unique coupling partner for 
palladium catalyzed reactions as well as nucleophilic substitution reactions. 
In Chapter 4, an in vivo efficacy study of my lead BODIPY PS was 
evaluated. In addition, the design and synthesis of a functionalized dye was 
performed to improve water solubility. The NIR BODIPY dye had two 
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carboxylic acid units that altered the pharmacokinetics and offered a 
platform for conjugation with biomolecules. 
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Chapter 2 
Singlet Oxygen Generation by Novel NIR BODIPY Dyes 
 
2.0. Introduction  
In this chapter, my aim was to rationally design highly photostable 
NIR BODIPY dyes with excitability > 700 nm and large extinction coefficient 
> 50,000 M-1cm-1 which appreciably generates singlet oxygen – the key 
cytotoxic agent in PDT. The motivation was to further advance the search 
for more effective second generation PSs for the treatment of tumors by 
PDT. I hypothesized that fusing thiophene moieties to the BODIPY core and 
subsequent substitution of other heavy atoms such as bromine would 
provide a 1O2 generator without compromising the excellent optical 
properties of BODIPY. 
2.1. Singlet Oxygen Applications 
2.1.1. Organic Synthesis 
  The importance of 1O2 in organic synthesis cannot be 
overemphasized. In solution it is generated using an appropriate PS that 
absorbs light and converted to the excited triplet state (intersystem 
crossing). In a type I process, the triplet state PS (94.3 kJ/mol) transfers an 
electron to biomolecules to form radicals which may interact with molecular 
21 
 
oxygen to yield reactive oxygen species such as hydroxyl ions, superoxides 
and hydrogen peroxides.61, 62 In a type II process there is a direct energy 
transfer to molecular oxygen to form singlet oxygen. 1O2 has a lifetime of 74 
minutes in gas phase and solvent dependent solution lifetime (CCl4: 59 ms, 
Benzene: 30 µs, H2O: 3.5 µs).63 The ene, hetero Diels Alder, [2+2] and 
[4+2] cycloaddition reactions have successfully made use of 1O2 in 
chemical transformations (Fig. 7).  
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Figure 7. Prototypical reactions of singlet oxygen 
2.1.2. PDT 
The reactivity of 1O2 makes it a useful cytotoxic agent, hence, its use 
in the non-invasive treatment of malignancies in PDT. Generators of 1O2 
used biologically and in particular in vivo must possess unique optical 
characteristics towards ideality. The ideal PS must possess the following 
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characteristics: 1) single pure compound with a chemically defined structure 
2) high 1O2 quantum yield Φ∆ 3) excitability in the NIR region >700 nm with 
a high molar extinction coefficient 4)  moderate fluorescence capacity 5) 
high photostability, and 6) high phototoxicity with minimal dark toxicity as 
well as low skin photosensitization in vivo. 
2.2. BODIPY PSs 
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY), since its first 
discovery in 1968,64 has attracted attention for various applications65 such 
as biological imaging and labeling,66 sensors,67 dye-sensitized solar cells 
(DSSC),68 light-emitting materials for electroluminescent devices, and 
PDT.69, 70 The photophysical properties of BODIPY dyes display excellent 
characteristics in relation to other dyes such as intense absorption and 
emission bands, high photostability, high fluorescence quantum yield, high 
extinction coefficient, and flexible modification for tuning absorption range 
and HOMO-LUMO gap.71 Recently, versatile synthetic approaches made 
the modifications of BODIPY feasible for achieving variable excited state 
properties including 1O2 generation by increasing intersystem crossing (S1 
T1 transition) by substituting heavy atoms to the BODIPY core to enhance 
spin orbit coupling.72 In current research practice, majority of BODIPY-
based PSs used in PDT are developed by the incorporation of heavy 
atoms, Br and I. Moreover the emergence of heavy-atom free BODIPY PSs 
is on the rise.73, 74 The development of BODIPY-based PSs thus far has a 
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limitation of reaching deeper tissues due to their relatively low absorption 
wavelength (<700 nm). Only the aza-BODIPY class has advanced in 
preclinical research. The need to take advantage of the excellent optical 
and photophysical properties of BODIPY to obtain NIR sensitizers is 
imperative. A summary of BODIPY PSs in current preclinical use shows the 
optical properties (fluorescence quantum yield, singlet oxygen quantum 
yield maximum absorption and emission in various solvents) and their 
photocytotoxicity values expressed as IC50 (or EC50) units (half maximal 
inhibitory concentration) in respective cell lines (Fig. 8). The summary gives 
an unambiguous basis to compare the current development to the new 
singlet oxygen generating NIR BODIPY dyes in this dissertation. Among the 
BDP PSs in Fig. 8, none has absorption > 700 which is in sharp contrast to 
our developed sensitizers with remarkable absorption in the NIR range of 
720 – 766 nm allowing for deeper tissue penetration for improved 
treatment. In addition, these dyes show enhanced fluorescence ability 
especially for 41, making it useful for multimodal application of diagnosis 
and therapy. 
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Figure 8. General singlet oxygen generating BODIPY dyes in 
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2.3. Synthesis of Novel NIR Dyes 
Drawing inspiration from work by Umezawa et al. I approached the 
synthesis of the BODIPY analogues with a rational incorporation of heavy 
atoms. Taking the BODIPY core, conjugated chalcogens such as furan and 
thiophene were fused to pyrrole units via a multi-step pyrrole cyclization. To 
induce a bathochromic shift to the NIR region I took advantage of the push-
pull effect in using the D-π-A strategy where methoxyphenyl units (D) and 
CF3 (A) were conjugated through fused BODIPYchromophore. 
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Scheme 1. Synthetic strategy of SO generating NIR BODIPY dyes 
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2.4. Results and Discussion 
2.4.1. Synthesis of BODIPY Derivatives 
The first step necessary for the synthesis of compounds KFL4, 39 – 
43 was the preparation of appropriate modified pyrrole derivatives. The 
syntheses were summarized in Scheme 1. 2-(4-methoxyphenyl)-4H-fura [3, 
2-b] pyrrole-5-carboxylic acid, 37a, a known compound and its thieno 
analogue, 2-(4-methoxyphenyl)-4H-thieno [3, 2-b] pyrrole-5-carboxylic acid 
37b, a new compound; were prepared according to literature procedure.60 
The respective aryl substitution in the first step was carried out following a 
Suzuki-Miyaura cross coupling in high yields (70 – 80%) employing [1, 1’-
bis (diphenylphosphino)-ferrocene] palladium (II) dichloride 
dichloromethane complex (1:1) as a catalyst. The known furopyrrole (36a), 
and the new thienopyrrole (36b), building blocks were synthesized by 
Hemetsberg-Knittel synthesis in high yields (72-75%) and were 
characterized by 1H-NMR and ESI - HRMS. The isolable dipyrromethene 
intermediates (38a and 38b) were formed as a result of a proposed acid 
mediated decarboxylation and subsequent condensation involving 
trifluoroacetic anhydride to install a CF3 group at the meso-position. The 
isolated intermediates were not characterized but dissolved in toluene with 
the addition of boron trifluoride etherate and triethylamine under reflux to 
give the desired BODIPY products KFL-4 which is a known compound and 
the new compound 39. Overall yields were satisfactory. Bromination of 
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KFL-4 and 39 as well as the degree of bromination exemplified in di (40, 
41) and tetra (42, 43) substituted new BODIPY analogues followed an 
abandoned bromine electrophilic aromatic substitution of pyrroles in the 
literature.76 The modified procedure utilizes bromine and trace iodine with 
varying equivalence in methylene chloride under reflux conditions. The 
brominated furo-based BODIPY analogues (40 & 42) were in slightly higher 
yields of ~50 % than the thieno-based BODIPY analogues (41 & 43) in ~30 
%. A direct explanation for the yield variance is not known. Di-brominated 
BODIPY analogues were obtained using 3 eq. of bromine and 1 mg iodine; 
while the tetra brominated BODIPY analogues were prepared using 6 eq. 
bromine and 2 mg iodine. A highly non-polar product was purified by 
column chromatography and characterized by 1H-NMR and EI-HRMS. The 
site of bromination of compounds 40 and 41 was confirmed using 1-D 
NOESY and ROESY respectively. The selective bromination on the 
furo/thieno rings might be due to the high electron density contributed by 
the proximal methoxyphenyl donor groups. 
2.4.2.  Bromination Sites of 40 and 41 by NOESY and ROESY Analysis 
Using one dimensional 1H-NMR techniques the sites of bromination 
for the di-brominated compounds 40 and 41 were determined with helpful 
insights from Dr. Susan Nimmo of the University of Oklahama NMR facility. 
Specifically, 1D-selective NOESY and ROESY experiment were employed 
for 40 and 41 respectively. The interest was in locating 1H – 1H correlation 
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to affirm the bromination on the furan/thiophene or the pyrrole rings. The 
principle of these experiments determines 1H – 1H proximity in a molecule 
by through-space Nuclear Overhauser Effect (NOE). A weak irradiation of 
the phenyl protons (A) in KFL-4/39, the precursor of 40/41 resulted in an 
increase in the population of the higher energy level in nearby non-
irradiated protons (B) and (C) through space (Fig. 9). The excess 
population after undergoing a T1 relaxation to a lower energy level gave 
signal intensities of the nearby protons (B) and (C). The irradiation of (B) 
gave signal intensities (A) and (D) suggesting a close proximity between the 
phenyl protons and the furan/thiophene proton (D). In the NOESY/ROESY 
of KFL-4 and 39, the interaction of D with B was observed. On the other 
hand, it was not detected in the NOESY/ROESY of 40 and 41, which is the 
indicative of bromine substitution on the furan or thiophene instead of the 
pyrrole ring. 
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Figure 9. Key NOEs showing sites of bromination in 39 and 41  
 
2.4.3. Optical Properties of BODIPY Dyes 
In solutions of different polarities using CHCl3 and THF, the BODIPY 
analogues displayed excellent optical properties and sharp bands (Fig. 10). 
The synthesized dyes in solution showed a vivid green absorption color. 
The incorporation of the thiophene, 39, induced red-shifts of 8 nm relative to 
KFL4 while maintaining a high molar extinction coefficient of 201 000M-1 
cm-1. A larger bathochromic shifts of ~20 nm (KFL442) and ~30 nm (39 
43) was observed when four bromine atoms were substituted to the 
modified core containing furan and thiophene moieties respectively (Table 
39 
41 
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1). The absorption maximum of 41 was inconsistent with the observed 
trends as it displayed a blue shift of 11 nm from its parent 39. The variation 
was well captured by the TDDFT calculations (Fig. 14) although a cause of 
this variation is not clear; I could speculate an alteration in geometry by the 
bromine attachment. All the BODIPY analogues displayed sharp emission 
bands in the NIR region ranging from 738 – 820 nm, with moderate 
quantum yields of fluorescence. The effective triplet population of the dyes 
could have caused the low fluorescence quantum yields of the 
tetrabrominated analogues. 
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Figure 10. Absorption and emission spectra of NIR BODIPY KFL4-43 in 
CHCl3 
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Table 1. Optical properties of Novel NIR BODIPY analogues 
Compound Solvent λab, nm λem, nm ε,  M-1cm-1 Φfa 
KFL4 CHCl3 723 738 253 000 0.56 
 THF 722 738 229 000 0.56 
39 CHCl3 731 754 201 000 0.37 
 THF 730 754 179 000 0.39 
40 CHCl3 738 756 242 000 0.37 
 THF 732 756 203 000 0.28 
41 CHCl3 720 754 89 000 0.45 
 THF 717 754 64 000 0.17 
42 CHCl3 744 765 94 000 0.28 
 THF 741 765 139 500 0.11 
43 CHCl3 766 820 75 000 0.11 
 THF 764 770 51 000 0.04 
 
aReference: KFL4 
 
 
2.4.4. Singlet Oxygen Generation  
Employing the indirect method for the determination of singlet 
oxygen, a comparative study on  all analogues in THF solutions was 
performed. The solutions were irradiated with broadband light, 400 nm - 
850 nm, at 0.5 mW/cm2. Singlet oxygen generation was analyzed 
experimentally by 1,3-diphenylisobenzofuran (DPBF), a well known singlet 
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oxygen scavenger. The photooxidation of DPBF was monitored by the 
decrease of the absorbance band at 410 nm upon irradiation. The 
experiments were performed at initial concentrations of 5 × 10-6 M of PS 
and 90 × 10-6 M of DPBF over a period of 18 min. 5-(4-Methoxyphenyl)-
10,15,20-triphenyl-21,23 dithiaporphyrin (CMP) was used as a reference 
PS. Previous experiments established that CMP has a high singlet oxygen 
quantum yield, Φ(1O2) = 0.7-0.8.77 Although compounds 39, 40, 42 did not 
show significant photooxidation of DPBF, compounds 41 and 43 showed 
fast oxidation of DPBF (Fig. 10). A 1.2 fold relative rate of photooxygenation 
of DPBF by 41 was recorded and a 0.5-fold relative rate for 43 (Table 2). 
The slower rate of 43 might be attributed to its low molar extinction 
coefficient at the irradiation wavelength of 764 nm and potential aggregation 
due to its extreme hydrophobicity. 
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Figure 11. Comparative singlet oxygen generation study of NIR BODIPY 
analogues 
 
Table 2. Relative rate
 
of DPBF oxidation by 41, 43 and reference standard 
Compound CMP 41 43 
Relative rate 1.0 1.2 0.5 
 
2.4.5. Photostability of BODIPY Analogues 
Photostability is one of the required characteristics for fluorescent 
probes as well as PSs. In particular, NIR dyes that are often photo-unstable 
require a thorough examination. It is also important to note that a number of 
second generation PDT agents, for example, bacteriochlorins suffer from 
photobleaching. Subjecting 39 – 43 to photobleaching kinetic studies in 
comparison to the clinically approved PDT agent, meta-
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tetrahydroxyphenylchlorin (m-THPC) and its NIR absorbing analogue, 
meta-tetrahydroxyphenylbacteriochlorin (m-THPBC); I observed high 
resistance to photobleaching. The first order plots revealed that 
photobleaching of all the NIR BODIPY dyes were slower than that of m-
THPBC. In addition, dye 41 had a rate constant of -0.001 min-1 and that of 
43 was comparable with that of mTHPC at -0.0033 min-1. Photobleaching 
was observed for dye 40, with a k value of -0.0055 min-1. Under the 
irradiation conditions, m-THPC photobleached rapidly at the initial 30 mins 
over the other BODIPY analogues including 40. 
 
  
Figure 12. Photobleaching kinetics of BODIPY analogues, m-THPC, and 
m-THPBC. 
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Photostability results were obtained by comparing 39 - 43 to m-
THPBC. m-THPBC was dissolved in methanol and 39 - 43 were dissolved 
in THF and the solutions were matched to the same absorbance at T = 0 
(m-THPBC = 0.036 mM). These solutions were irradiated with a xenon arc 
lamp source at an intensity of 100 mW/cm2 using a water filter and two 
glass filters (>400 nm and <800 nm). The stability was monitored by UV 
spectrophotometer over a period of 1 h at 10 min interval following the 
diminution of band I (m-THPBC = 735 nm) and the bands of 39 - 43 at the 
respective absorption maxima.  
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Figure 13. UV spectra obtained during a photobleaching experiment 
2.4.6. Computational and Theoretical Insight 
To enlighten our understanding of the excited state in predicting the 
absorption behavior of these BODIPY analogues, theoretical and 
computational characterization using density functional theory (DFT) was 
performed.78 Geometry optimization of these compounds was carried out 
using the 6-311 G* basis set while the electronic excitations corresponding 
 to the absorption spectra 
(TDDFT) and the PBEPBE correlation functional in vacuo (gas phase) as 
expressed by Gaussian 09.
distribution moving from the HOMO where electrons are spread throughout 
the molecule and in the LUMO, where the acceptor CF
electrons (Fig. 14). The observation affirms the D
computationally generated TDDFT calculations predicted strong 0
absorption maxima (π
relatively small deviations from the
as observed in Table 3. The experimental data obtained from absorption 
spectra correlated we
analogues as seen in the observed trend (Fig
spectral shift could be attributed to mainly solvent effects
Figure 14. Frontier molecular 
 
40 
were calculated with time-dependent
79
 The frontier molecular orbital sho
3 
-π-A strategy. 
 – π*) of compounds 39 - 43 in the NIR region with 
 experimental data (∆E = 0.03 
ll with calculated excitation energies in vacuo 
. 15). The differences i
. 
orbital of BODIPY 41 
-DFT 
wed electron 
moiety pulls 
The 
-0 
- 0.15 eV) 
of the 
n 
 
41 
 
 
Figure 15. Observed trend for calculated excitation energies and 
experimental absorption maxima in eV 
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Table 3. TDDFT-Calculated Excitation Energies for the Lowest Transition 
(eV, nm), Oscillator Strengths (f), and Experimental Absorption Maxima 
(exp) 
Dye State Excitation E (eV, nm) f Exp (eV, 
nm) 
KFL4 S1 HL (103%) 1.87 (662) 1.66 1.72 (723) 
      
39 S1 HL (81%) 1.72 (718) 0.47 1.69 (731) 
 
40 S1 HL (96%) 1.73 (717) 1.28 1.68 (738) 
 
41 S1 HL (22%) 1.78 (697) 0.54 1.72 (720) 
 
42 S1 HL (97%) 1.71 (723) 1.23 1.66 (746) 
 
43 S3 H2L (79%) 1.64 (757) 0.40 1.61 (766) 
 
 
2.5. Conclusion 
In this chapter, I focused on developing novel NIR BODIPY dyes with 
propensity to generate singlet oxygen, a key cytotoxic agent in PDT. I used 
the synthetic strategy of ring fusion of furan and thiophene moieties to the 
BODIPY core for extended π-conjugation in inducing bathochromic shift into 
the NIR region. Furthermore, in addition to the thiophene moieties, I carried 
out an aromatic electrophilic substitution with bromine to impart a heavy 
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atom effect for enhanced ISC in generating 1O2. The chemical strategies 
employed led to the development of BODIPY dyes with absorption in the 
NIR from 720 nm – 766 nm and emission of 738 – 820 nm. The brominated 
sulfur analogues displayed a good generation of 1O2 with high resistance to 
photobleaching relative to clinically approved Foscan and its NIR absorbing 
analogue, m-THPBC. The BODIPY dye, 41, in addition to high 1O2 
generation displayed a brightness (BT=ε х Φf), 40, 050 and 10, 880 M-1 cm-
1
 in CHCl3 and THF, respectively, making it a promising theranostic 
candidate for PDT and in vivo diagnostics. Moreover, this work confirms the 
use of computational DFT methods as a useful tool in the design of efficient 
BODIPY candidates based on the close correlation of experimental to 
calculated data. 
These new sensitizers displayed a great potential for NIR dual-functioning 
PSs with absorption at long wavelengths and effective generation of both 
fluorescence and singlet oxygen. 
 
2.6. Experimental Section 
2.6.1. General Experimental Procedure 
Chemical reagents and solvents of analytical grade were purchased 
from commercial suppliers (Sigma-Aldrich Co. or Acros Organics) and were 
used without purification. THF was distilled from Na and benzophenone 
prior to use. Dichloromethane used was distilled from CaH2. Air sensitive 
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reactions were performed under an atmosphere of nitrogen. Nuclear 
magnetic resonance spectra were recorded in CDCl3, CD2Cl2, Acetone-d6 
or DMSO-d6 on Bruker AM-400 or Varian 300 MHz spectrometers. 
Chemical shifts are given in parts per million relative to TMS or 7.23 ppm 
for residual CHCl3 for 1H-NMR and coupling constants were measured in 
Hz. Electron Impact (EI) using a ThermoFinnigan MAT 95 XL spectrometer 
and determined at an ionized voltage of 70 eV and Electrospray Ionization 
(ESI) Mass Spectrometer measurements were recorded on Bruker Mass 
Spectrometer from SUNY Buffalo and South Dakota State University Mass 
Spectrometry Facilities respectively. The compounds from furan were 
synthesized based on the reference.60 
Geometry optimization was carried out using Gaussian 09 and 
Spartan 08 modules. 
 
2.6.2. 4-methoxyphenylboronic acid (33)*.80 Magnesium (4.20 g, 174 
mmol) was placed in a dry 2-neck round bottom flask and dry THF (50 ml) 
was added and refluxed for 2 h. 4-bromoanisole (27.20 g, 145 mmol) in dry 
THF (100 ml) was added slowly and after 5 h the reflux was stopped and 
the solution was cooled to room temperature. The cooled solution (4-
methoxypheny magnesium bromide) was slowly added to trimethylborate 
(19.60 g, 188 mmol) in dry THF (100 ml) at 0 °C via  a cannula. After stirring 
the reaction mixture overnight at room temperature, the reaction was 
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filtered and the solid obtained immersed in water. The aqueous solution 
was acidified with 1 N HCl (aq.) and extracted with ethyl acetate (3 times). 
The organic layer was washed with water and dried over anhydrous 
Na2SO4 and the solvent removed under vacuum. The solid residue was 
purified by recrystallization from toluene to obtain a pure white solid, 33 
(19.60 g, 89 % [based on 1H-NMR]). 1H-NMR (CDCl3) : 8.17 (d, J = 8.6 Hz, 
2H), 7.02 (d, J = 8.6 Hz, 2H), 3.89 (s, 3H), B-OH (not observed).*Known 
2.6.3. 5-(4-methoxyphenyl)-furan-2-carbaldehyde (35a)*.60 33 (4.85 g, 
31.9 mmol) and 5-bromo-2-furaldehyde (5.59 g, 31.9 mmol) were dissolved 
in toluene (200 ml). Ethanol (50 ml) and 2 M aqueous Na2CO3 (30 ml) was 
added and nitrogen was bubbled through the reaction mixture for 30 min. 
[1,1-bis(diphenylphosphino)-ferrocene] palladium (II)dichloride 
dichloromethane complex (1:1) (167 mg, 0.20 mmol) was added and 
heated to 80 °C for 14 h. The reaction mixture was coo led and the ethanol 
evaporated under vacuum. The resulting solution was washed with water 
and brine and dried over  anhydrous Na2SO4 and concentrated to obtain a 
brown liquid. Column chromatography (silica gel) was used to purify the 
compound by gradient elution with ethyl acetate: hexane (5:95 – 25:75) as 
mobile phase with the target compound eluting at 20:80 ethyl acetate: 
hexane (monitored by TLC) as a yellow liquid (4.10 g, 85% [based on 1H-
NMR]). 1H-NMR (CDCl3) : 9.53 (s, 1H), 7.66 (d, J = 8.8 Hz, 2H), 7.25 (d, J 
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= 8.8 Hz, 1H) 6.87 (d, J = 8.8 Hz, 2H), 6.65 (d, J = 8.8 Hz, 1H), 3.76 (s, 3H). 
*Known 
2.6.4. Ethylazidoacetate*.81 Ethylbromoacetate (6.40 g, 38.5 mmol) was 
dissolved in acetone and transferred into a round bottom flask. While 
stirring at room temperature (25 °C) dissolved sodium a zide (5.0 g, 77 
mmol) in water was added slowly. Stirring was continued for 1.5 h and the 
reaction was stopped. The acetone was evaporated and dichloromethane 
was used to extract the compound. The extract was washed with water and 
dried over anhydrous MgSO4 and concentrated to obtain a pale yellow liquid 
(4.35 g, 87 % [based on 1H-NMR]). 1H-NMR (CDCl3, 400 MHz): δ 4.20 (q, J 
= 7.1 Hz, 2H), 3.82 (s, 2H), 1.25 (t, J = 7.1 Hz, 3H).  IR: (KBr, cm-1): 2110 
(νN≡N).*Known 
2.6.5. 2-(4-Methoxyphenyl)-4H-furo[3,2-b]pyrrole-5-carboxylic acid 
ethyl ester (36a)*.60 Ethylazidoacetate (13.0 g, 100 mmol) and 5-(4-
methoxyphenyl)-furan-2-carbaldehyde (35a) (5.8 g, 29 mmol) were 
dissolved in anhydrous ethanol (250 ml) and stirred at 0 °C under a nitrogen 
atmosphere. 21 % NaOEt in EtOH solution (42.9 ml, 100 mmol) was added 
dropwise to the mixture and stirring continued for 2 h. A saturated solution 
of ammonium chloride was added to form a yellow precipitate which was 
collected by filtration and vacuum dried. The resulting brown residue was 
dissolved in toluene and refluxed for 1.5 h to complete the cyclization of the 
derived pyrrole. The solvent was evaporated and purified by column 
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chromatography (silica gel) using gradient elution of ethyl acetate – hexane 
(5 – 30  95 – 70) to obtain a brown solid (3.00 g, 48 % [based on 1H-
NMR]). 1H-NMR (CDCl3, 400 MHz) : 8.67 (s, 1H), 7.59 (d, J = 8.8 Hz, 2H), 
6.87 (d, J = 8.8 Hz, 2H), 6.72 (s, 1H), 6.50 (s, 1H), 4.27 (q, J = 7.1 Hz, 2H), 
3.78 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H).*Known 
2.6.6. Ethyl 2-(4-methoxyphenyl)-4H-thieno[3,2-b]pyrrole-5-carboxylate 
(36b): Ethylazidoacetate (5.01 g, 38.8 mmol) and 5-(4-
methoxyphenyl)thiophene-2-carbaldehyde (35b) (2.12 g, 9.7 mmol) was 
dissolved in anhydrous EtOH (250 ml) under a nitrogen atmosphere at 0 °C 
and stirred for 20 min. 21% NaOEt in EtOH solution (2.64 g, 38.8 mmol) 
was added dropwise at 0 °C over 20 min. The reaction t urned dull orange in 
color. After 30 min, the reaction solution was taken out of the ice bath and 
stirred for an additional 1.5 h.  A saturated aqueous solution of NH4Cl (10 
ml) was added dropwise to facilitate precipitation. The yellow precipitate 
was collected by vacuum filtration and washed with water. The washed 
solid was collected and allowed to dry. The dried solid was dissolved in 30 
ml of toluene and refluxed for 1.5 h to complete the cyclization of the 
derived pyrrole. Toluene was removed and the residue purified by column 
chromatography (silica gel) using gradient elution with ethyl acetate – 
hexane (5 – 30  95 – 70) to give a yellow amorphous solid (1.00 g, 47 %, 
[based on 1H-NMR]).  1H-NMR (CDCl3, 400 MHz): δ 8.95 (s, 1H), 7.55 (d, J 
= 8.0 Hz, 2H), 7.11 (s, 1H), 7.07 (s, 1H), 6.93 (d, J = 8.0 Hz, 2H), 4.34 (q, J 
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= 7.1 Hz, 2H), 3.84 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H). HRMS (EI) (m/z): 
Calculated for C16H15NO3S: 301.0773;   Found: 301.0826 [M]+. 
2.6.7. 2-(4-Methoxyphenyl)-4H-thieno[3,2-b]pyrrole-5-carboxylic acid 
(37b): 36b (0.30 g, 1.1 mmol) was dissolved in EtOH (~10 ml). NaOH (0.62 
g, 15.5 mmol) in water (5 ml) was added to the solution and refluxed for 1 h. 
The reaction was cooled to room temperature and further cooled in an ice 
bath. The reaction mixture was then acidified with concentrated HCl. The 
precipitate was filtered, washed with water and dried under vacuum. A dark 
green solid was obtained (0.22 mg, 70 % [based on 1H-NMR]). 1H-NMR 
(DMSO-d6, 400 MHz): δ 12.36 (s, 1H), 11.93 (s, 1H), 7.60 (d, J = 8.0 Hz, 
2H), 7.22 (s, 1H), 7.01 (s, 1H), 6.99 (d, J = 8.0 Hz, 2H), 3.79 (s, 3H). HRMS 
ESI (m/z): Calculated for C14H11NO3S: 273.0460; found: 273.0459 [M+H] +. 
2.6.8. 2,8-Di(4-methoxyphenyl)-11-trifluoromethyl-dithieno[2,3-b]-[3,2-
g]-5,5-difluoro-5-bora-3a,4a-dithio-s-indacene (39). 37b (0.20 g, 0.7 
mmol) was dissolved in TFA (10 ml) at 40 °C, an intens e green color 
appeared. Trifluoroacetic anhydride (2 ml) was added at 40 °C and the 
temperature was then raised to 80 °C and stirring was co ntinued for 30 min, 
all under a nitrogen atmosphere. The reaction was quenched as it was 
poured into aqueous NaHCO3 solution containing crushed ice. The dark 
green precipitate was filtered, washed with water and dried in vacuo. The 
solid was dissolved in dry toluene (47 ml) and stirred for 5 min at room 
temperature under a nitrogen atmosphere for complete dissolution. Boron 
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trifluoride dietherate (1 ml) and triethylamine (0.5 ml) were added and the 
temperature was raised to 80 °C and stirring continued for 30 min. After 
cooling, the reaction solution was diluted with toluene and washed with 
aqueous NaHCO3, water and brine. The solvent was evaporated to obtain a 
crude mixture, which was purified by column chromatography (silica gel) 
using chloroform/hexane (80:20) as the mobile phase. A green metallic 
solid was obtained (73 mg, 33 % [based on 1H-NMR]). 1H-NMR (CD2Cl2, 
400 MHz): δ 7.76 (d, J = 8.0 Hz, 4H), 7.34 (s, 2H), 7.32 (s, 2H), 7.03 (d, J = 
8.0 Hz, 4H), 3.91 (s, 6H). HRMS EI (m/z): Calculated for C28H18BF5N2O2S2: 
584.0823; Found: 584.0825 [M]+. 
2.6.9. 3,7-Dibromo-2,8-di(4-methoxyphenyl)-11-trifluoromethyl-
difuro[2,3-b]-[3,2-g]-5,5-difluoro-5-bora-3a,4a-diaza-s-indacene (40). 
KFL-4 (0.06 g, 0.1 mmol) along with I2 (0.001 g) were dissolved in CH2Cl2 
(15 ml). A solution of Br2 (0.10 g, 0.7 mmol) in CH2Cl2 (5 ml) was added 
dropwise and stirred at 40 °C for 12 h. The reaction mixture was neutralized 
with aqueous Na2CO3 solution and the aqueous layer was separated from 
the organic layer. The aqueous layer was further extracted with diethyl 
ether and the combined organic layers were dried over anhydrous Na2SO4 
and the solvents removed by evaporation under vacuum to obtain a brown 
solid (40 mg, 52 % [based on 1H-NMR]). 1H-NMR (CDCl3, 400 MHz) : 8.21 
(d, J = 9.0 Hz, 4H), 7.03 (d, J = 9.0 Hz, 4H), 6.80 (s, 2H), 3.84 (s, 6H). 
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HRMS EI (m/z): Calculated for C28H16BBr2F5N2O4: 709.9470; found: 
709.9519 [M] +. 
2.6.10. 3,7-Dibromo-2,8-di(4-methoxyphenyl)-11-trifluoromethyl-
dithieno[2,3-b]-[3,2-g]-5,5-difluoro-5-bora-3a,4a-diaza-s-indacene (41). 
Following the method used to prepare compound 40, the starting material 
39 (0.05 g, 0.1 mmol), was used with I2 (0.001 g) and Br2 (0.04 g, 0.3 mmol) 
to obtain compound 41 (25 mg, 37 % [based on 1H-NMR]). Interestingly, 
while one doublet peak for four protons at 2-position of 4-methoxyphenyl 
groups was observed from the other BODIPY derivatives, compound 41 
showed two doublet peaks for the corresponding four protons. It might be 
due to hindered rotation of methoxyphenyl group by the substituted 
bromines in 41. 1H-NMR (CD2Cl2, 300 MHz) : 7.84 (d, J = 9.0 Hz, 2H), 7.76 
(d, J = 9.0 Hz, 2H), 7.64 (s, 1H), 7.05 (dd, J = 9.0 Hz, 4H), 3.89 (s, 6H). 
HRMS EI (m/z): Calculated for C28H16BBr2F5N2O2S2: 741.9013; found: 
741.8978 [M]+. 
2.6.11. 3,7,9,12-Tetrabromo-2,8-di(4-methoxyphenyl)-11-
trifluoromethyl-difuro[2,3-b]-[3,2-g]-5,5-difluoro-5-bora-3a,4a-diaza-s-
indacene (42). KFL-4 (0.13 g, 0.2 mmol) along with I2 (0.002 g) were 
dissolved in CH2Cl2 (15 ml). A solution of Br2 (0.33 g, 2.1 mmol) in CH2Cl2 
(5 ml)
 
was added dropwise and stirred at 40 °C for 12 h. The reaction 
mixture was neutralized with aqueous Na2CO3 solution (20 %) and the 
aqueous layer was separated from the organic layer. The aqueous layer 
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was further extracted with diethyl ether and the combined organic layers 
were dried over anhydrous Na2SO4 and the solvents removed by 
evaporation to obtain a brown solid (61 mg, 30 % [based on 1H-NMR]). 1H-
NMR (CDCl3, 300 MHz) :  8.20 (d, J = 8.9 Hz, 4H), 6.97 (d, J = 8.9 Hz, 4H), 
3.84 (s, 6H).  HRMS EI (m/z): Calculated for C28H14BBr4F5N2O4: 867.7659; 
found: 867.7673 [M]+.  
2.6.12. 3,7,9,12-Tetrabromo-2,8-di(4-methoxyphenyl)-11-
trifluoromethyl-dithieno[2,3-b]-[3,2-g]-5,5-difluoro-5-bora-3a,4a-diaza-
s-indacene (43). Following the method used to prepare compound 42, the 
starting material 39 (0.09 g, 0.2 mmol), was used with I2 (0.002 g) and Br2 
(0.29 g, 2.0 mmol) to obtain compound 43 (27 mg, 20 % [based on 1H-
NMR]). 1H-NMR (CDCl3, 300 MHz) : 7.71 (d, J = 9.2 Hz, 4H), 6.96 (d, J = 
9.2 Hz, 4H), 3.81 (s, 6H). HRMS EI (m/z): Calculated for 
C28H14BBr4F5N2O2S2: 899.7202; found: 899.7197 [M]+. 
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Chapter 3 
Versatile Synthesis of NIR BODIPY Dyes via Palladium Catalyzed 
Cross-coupling  
 
3.0 . Introduction 
The development of NIR organic probes for non-invasive optical imaging 
and photo-induced light therapy is an attractive enterprise for medical 
applications. Difficult synthesis, lack of photostability, limited opportunities 
for functionalization, and poor solubility for use biologically are a number of 
challenges in the development of NIR organic probes. The photostability, 
high molar extinction coefficient, sharp absorption and emission bands of 
BODIPY are well known and so make it a reliable chromophore for use in 
diagnosis and therapy. However, synthesis for NIR BODPY analogs still 
remains a major challenge. To address this problem, a versatile but robust 
strategy is needed, which involves a flexible and facile synthesis to obtain 
customizable target analogues and intelligent incorporation of functional 
moieties to maintain their excellent photophysical properties. 
In this chapter, I created a reactive fused BODIPY aryl halide 
intermediate (BDP635, Scheme 2) displaying versatility with multiple Pd-
catalyzed cross coupling reactions as well as nucleophilic substitution 
reactions (Fig. 16). A stepwise consideration of the strategy for NIR 
BODIPY involved 1) preparation of versatile BODIPY aryl halide coupling 
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partner absorbing in the visible region, 2A) Pd- catalyzed cross coupling 
reactions of the BODIPY aryl halide such as Suzuki, Stille, Heck for 
extended conjugation, or 2B) nucleophilic substitution reactions of the 
BODIPY aryl halide for modest red-shifting. 3) Once NIR BODIPY cores 
were obtained, these could be further modified with various functional 
groups to modulate their physicochemical properties such as water 
solubility and tendency of aggregation (Chapter 4).  
S-BODIPY
CF3
BrBr S-BODIPY
CF3
ArAr
1. Pd-catalyzed
2. Nu. substitution
 
Figure 16.  Schematic diagram of versatile synthetic strategy 
 
3.1. Synthesis of Versatile BODIPY Aryl Halide 
The BODIPY core is known for its high electron density and 
therefore, susceptible to electrophilic substitution reaction. Selective 
halogenation of the BODIPY exposes it to a plethora of reactions from 
nucleophilic to transition metal catalyzed cross coupling. Simple BODIPY 
units have been used in this regard with their 3, 5 and 2, 6 positions 
halogenated for coupling or substitution to aryl moieties. Motivated by the 
prototypes of short-wavelength absorbing dyes, I rationally designed the 
scaffold which benefits from ring fusion of aromatic heterocycles to the 
BODIPY core but maintains the electronic properties of the BODIPY core. 
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To achieve the versatile BODIPY aryl halide (BDP635), I synthesized 
the pyrrole building block (46) from bromo-thiophene carbaldehyde (44) by 
first reacting it with ethylazido acetate (45) and then heating at high 
temperatures (Scheme 2). The ester was subjected to basic hydrolysis. The 
carboxylic version of the modified pyrrole (47) was formed after 
acidification. The bromo-substituted modified pyrrole (47) underwent a 
condensation via an acid catalyzed decarboxylation of the pyrrole and with 
a subsequent reaction with TFA anhydride installed a CF3 at the meso-
position of the formed dipyrromethene unit. The di-bromo BODIPY alkyl 
halide is prepared by the reaction of the dipyrromethene unit with boron 
trifluoride and triethylamine. 
 
SBr
H
O N3 O
O
1. Acetone-H2O, rt.
2. NaOEt/EtOH, 0oC
3. Toluene, reflux
S
N
Br
O
O
H
S
N
Br
OH
O
H
NaOH/EtOH-H2O
N
B
N SS
CF3
F FBr Br
λ max abs 635 nmCH2Cl2,
44
45
46
47
BDP635
NH N SS
CF3
Br Br
1. TFA, 40 oC
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Scheme 2. Synthetic approach for BDP635 
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3.2. Results and Discussion 
 
3.2.1. Synthesis of BDP635 
The preparation of starting material, 2-bromo-4H-thieno[3, 2-
b]pyrrole-5-carboxylic acid, 47, a known compound, followed the 
Hemetsberg-Knittel synthesis of ethylazidoacetate (45) and 5-bromo-2-
carbaldehyde (44) with subsequent hydrolysis led to 47 in high yields (75%) 
isolated by precipitation and filtration. Compound 47 was subjected to the 
established condensation with TFA and trifluoroacetic anhydride. The 
isolable dipyrromethene solid was not characterized but used in the next 
step involving a reaction with boron electrophile, BF3 etherate in the 
presence of triethylamine to obtain the new BODIPY halide, BDP635. The 
desired BODIPY was isolated by silica-gel column chromatography by 
pouring the solution through the column to obtain the pure blue solution. A 
standard work-up was not used due to the decomposition of the target 
compound upon rotary evaporation that might be a result of a reaction of 
residual TEA with the highly electrophilic BODIPY product. The purified 
BDP635 was characterized by 1H-NMR and EI-HRMS.  
 
 
3.2.2. X- Ray Structure of BDP635 
 The BDP635
slow evaporation from a clear blue, concentrated solution of 
CH2Cl2 at room temperature in a round bottom flask. The black plate
crystal of dimensions 0.44 x 0.41 x 0.08 mm was used for 
analysis. Measurements were performed using a diffractometer with a 
Bruker APEX CCD
radiation (λ = 0.71073
geometry almost tetrahedral with a
F-C and remained close to tetrahedral geometry at 106.7 (2)
o
. The Br-C bond lengths were identical at 1.861 (3) 
remained planar in fusion with the thiophene aromatic.
 
Figure 17. ORTEP view of the X
displacement ellipsoids 
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 single crystal of a monoclinic system was obtained by 
the structural 
 area detector and graphite-monochromated Mo K
 Å). The sterically crowded boron center maintained a 
n N-B-N angle of 105.1 (2) o, while the C
 o
 and 106.3 (2)
Å. The BODIPY core 
 
 
-ray crystal structure of BDP635
were drawn at the 50 % probability level.
BDP635 in 
-like 
α 
-
 
 
. The 
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3.2.3. Quantum chemistry and theoretical approach 
To gain insight into the electronic properties of the so called versatile 
BODIPY alkyl halide, BDP635, electron density maps of the frontier 
molecular orbitals (HOMO and LUMO) were calculated using density 
functional theory (DFT) calculations in tandem with the Becke’s three-
parameter hybrid functional82 and the Lee–Yang–Parr correlation (B3LYP). 
83
 Gaussian 09 with an appropriate basis set of 6-311G* was used for the 
calculations. BDP635 showed similar electron density maps to the 
previously synthesized NIR BODIPY dyes with the exception of donor 
fragments. In the ground state, the electrons at HOMO are held in the fused 
BODIPY chromophore and once excited (LUMO), the electrons move to the 
trifluoromethyl electron withdrawing unit at the meso position (Fig. 18). The 
observed electron flow is expected in the design strategy for the donor-
acceptor system. To gain insight into the excited states as a result of the 
strong absorption band in the visible region, a TDDFT excited state 
calculation at the B3LYP/6-311G* level in vacuo and the C-PCM model was 
performed, giving rise to a variation of ~135 nm between calculated vs. 
experimental (Fig. 18). Considering the strong SoS1 transitions with 
oscillator strength ~0.12, the variation could be attributed to solvent effects. 
On the whole, the insight offered confidence as it supported the rational of 
 building NIR absorbing BODIPY with a building block strongly absorbing in 
the visible range. 
 
Figure 18. FMO of BDP635
 
3.3. Palladium-catalyzed
Carbon-carbon bond formation reactions are
synthesis for a wide spectrum of uses mainly via cross coupling 
Transition metals have 
coupling reactions.84
employed largely. Palladium is arguably the most used and thoroughly 
investigated.85 To a large extent palladium uses iodides and bromides as its 
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 and excited state UV prediction 
 Cross Coupling  
 essential in chemical 
played an active role in promoting several cross
 Copper, palladium, nickel and recently Iron have been 
 
reactions. 
-
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organic acceptors but recently alkyl phosphines, N-heterocyclic carbenes 
and aryl chlorides have become applicable.86 
 
3.3.1. Suzuki cross coupling 
With the establishment of organoborons and alkylhalides, 
phosphines or triflates as useful reagents for carbon-carbon bond formation 
I capitalized on the benefits of Suzuki cross coupling to extend the BODIPY 
and consequently push its absorption towards NIR (Fig. 19). Among the 
benefits considered were the 1) mild conditions, 2) commercial availability 
or established methodology for boronic acids, 3) functional group tolerance 
and less toxic by-products generated. 
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Scheme 3. Suzuki reaction coupling 
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Figure 19. Structures of SBDPiRs via Suzuki coupling 
 
3.3.2. Heck reaction 
In the D-π-A system an approach to extend the π-conjugated system 
sandwiched by the donor and acceptor systems was performed. Hence the 
Heck reaction offered us a useful tool for building substituted olefins. 
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Scheme 4. Heck reaction coupling 
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Figure 20. Structures of SBDPiR via Heck reaction 
 
3.3.3. Stille coupling 
A great alternative to the organoborane reagent are the 
organostannanes (organotin) as typified in the Stille cross coupling. It was 
rationed that building an organic electrophile would be an excellent coupling 
partner for organostannanes. In addition, the wide functional group 
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tolerance, less sensitivity to moisture and relatively easier preparation of 
organotins made it a worthwhile venture to pursue. 
N
B
NS S
CF3
F FBr Br
N
B
NS S
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Na2CO3(aq), Pd(PPh3)4,
toluene, 80 oC
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Scheme 5. Stille cross-coupling reaction  
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Figure 21. Structure of SBDPiR via Stille coupling 
 
3.3.4. Nucleophilic substitution 
In order to explore the reactivity of the key intermediate as a 
BODIPY electrophile, substitution reactions with nucleophiles from the 
chalcogen group; O and S was performed (Fig. 22). Relatively fast 
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reactions were observed with appreciably moderate to high yields, 
confirming the versatility of BDP635. 
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Scheme 6. Nucleophilic substitution reaction  
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Figure 22. Structures of SBDPiR via nucleophilic substitution reaction 
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3.4. Results and Discussion 
3.4.1. Synthesis 
According to mesomeric structures of the indigenous BODIPY core, 
the 2, 6 (β) positions bear the least positive charge; making it susceptible to 
electrophilic attack. Using the indigenous core as a prototype an estimate 
that the 2, 8 positions of the modified thieno-pyrrole BODIPY (BDP635) 
bears similar electronic properties was made. In addition, the CF3 group at 
the meso position renders the BODIPY as a more electrophilic organic 
moiety for various reactions. BDP635 was used in several palladium 
catalyzed cross coupling reactions, displaying similar reactivity as an 
organic electrophile in comparison to various halogenated BODIPY 
reported in literature.  
First, in the Suzuki cross coupling  BDP635  showed excellent 
reactivity in comparison to that of the hexabromo-BODIPY reported in the 
literature.87 In this Pd-catalyzed cross coupling reaction, our dibromo-
modified BODIPY (BDP635) reacted with different aryl boronic acids in a 
three component solvent system of water, THF and toluene, using 
Pd(PPh3)4 as catalyst with Na2CO3 as a base. The reaction was heated at 
80 °C for 2-3 h depending on arylboronic acid (Scheme 3). All compounds 
except SBDPiR731 were new compounds obtained in satisfactory yields. 
Compounds SBDPiR740, SBDPiR735, SBDPiR731, SBDP730 (Fig. 19) 
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were obtained using 4-hydroxyphenylboronic acid, thiopheneboronic acid, 
methoxyphenylboronic acid and 3, 4, 5-trimethoxyphenyl boronic acid 
respectively in moderate yields of ~50 %. SBDPiR730 was synthesized to 
demonstrate the relatively facile and cost effective approach in making the 
known (made by our research group) SBDPiR730 in scheme 1 as 
compound 39. The use of N,N-dimethylaminophenylboronic acid resulted in 
SBDPiR840, most red-shifted in the synthesized dye series. The enhanced 
resonance effect in the N, N-dimethylaminophenylboronic acid might have 
contributed to the relatively faster reaction in relation to the other substrates 
in the series. 
Second, the reactivity of BDP635 was further validated in the Heck 
coupling reaction as relatively milder conditions were applied to obtain 
desired  NIR BODIPY in relation to the 3,5 halogenated BODIPY in 
literature.48 In an anhydrous toluene solution of, BDP635 with respective 
styrene and 4-methoxystyrene substrates were heated to 80 °C for 6 h.  
Palladium (II) acetate was used as catalyst and triphenylphosphine as 
ligand. It is interesting to point out that shorter reaction times yielded the 
monosubstituted analogues as observed on TLC and UV-vis spectroscopy 
but were not isolated and characterized. The commonly used base for Heck 
coupling, triethylamine, was not employed for these substrates as I suspect 
a possible nucleophilic attack of the base with BDP635, instead, Na2CO3 
was used. SBDPiR755 and SBDPiR790 (Fig. 20) were obtained in decent 
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yields of 25 – 30 %. A remarkable bathochromic shift was observed due to 
the external olefin added to the existing BODIPY π-system to afford a D-π-
π-A system. 
Third, BDP635 was allowed to react under the Stille coupling 
reaction conditions for 1 h with equimolar portions of tetraphenyltin reagent. 
Pd(PPh3)4 was used as catalyst with an aqueous solution of Na2CO3 (1M) 
to afford the SBDPiR690 (Fig. 21) in a di-substituted fashion.  
Finally, I demonstrated SNAr reactions on BDP635 with varied 
nucleophiles such as thiophenol, 4-methoxyphenol and biphenylphenol to 
afford SBDPiR700, SBDPiR650_OMe and SBDPiR650 (Fig. 22) 
respectively. BDP635 showed similar reactivity to that of 3,5-dihalogenated 
BODIPY52 and bromoBODIPYs developed by Jiao et al.51 The reaction 
conditions for the substrates utilized minimal amount of acetonitrile and 
K2CO3 as base to establish the SNAr. The reaction yields were good in the 
order of 70 %. 
All substrates were purified by silica gel column chromatography and 
characterized by 1H-NMR and EI-HRMS. All synthesized analogs were new 
compounds except SBDPiR731 (39) which was synthesized first by our 
earlier study.59 
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The reaction conditions and yields of the palladium-catalyzed 
coupling reactions as well as SNAr reactions of BDP635 are summarized in 
Table 4. 
 
Table 4: Summary of reaction conditions of palladium catalyzed and 
nucleophilic substitution of SBDPiRs 
Reagent Solvent Temp/ºC Reactio
n time/h 
Product Yield/
% 
4-Methoxyphenol CH3CN reflux 1 SBDPiR650_OMe 25 
4-Phenylphenol CH3CN reflux 1 SBDPiR650 70 
Thiophenol CH3CN reflux 0.5 SBDPiR700 30 
Tetraphenyltin Toluene 80 1 SBDPiR690 30 
Styrene Toluene 80 6 SBDPiR755 20 
4-Methoxystyrene Toluene 80 6 SBDPiR790 25 
4-Hydroxyboronic 
acid 
Tol/THF/H2Oa 80 3 SBDPiR740 54 
4-
methoxyphenylboro
nic acid 
Tol/THF/H2Oa 80 3 SBDPiR731 50 
3,4,5-
trimethoxyphenyl 
boronic acid 
Tol/THF/H2Oa 80 2 SBDPiR730 45 
N,N-dimethylphenyl 
boronic acid 
Tol/THF/H2Oa 80 2 SBDPiR840 20 
2-thiopheneboronic 
acid 
Tol/THF/H2Oa 80 1 SBDPiR735 50 
Tol – toluene; [a] 1:1:1(v/v) 
 
3.4.2. Optical Properties of SBDPiRs 
The SBDPiRs showed excellent photophysical with high extinction 
coefficients sharp absorption and emission bands similar to the cyanines 
and phthalocyanines. The high extinction coefficient could be attributed to 
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the planarity of these SBDPiRs as shown by the X-ray single crystal 
analysis of the precursor BDP635. The optical characteristics validated the 
rational approach used in the design. The previous D-π-A strategy was 
adopted displaying absorption spectra with lowest energy absorbing 
maximally 650 – 840 nm which corresponds to the 0-0 band of SoS1 (π-
π*) transition of the BODIPY framework. The nucleophilic substituted 
SBDPiRs exhibited lowest absorption maxima among the series due to the 
break in conjugation as a result of the heteroatom (O, S) insertion. The 
impact of the sulfur heavy atom in SBDPiR700 gave a pronounced 
bathochromic shift relative its oxygen analogues. In contrast, the Suzuki 
and Stille made SBDPiRs as a result of uninterrupted conjugation to 
aromatics (SBDPiR690), heteroaromatics (SBDPiR735) and aromatics 
bearing donor moieties such as the 4-methoxyphenyl, 4-hydroxyphenyl and 
3,4,5-trimethoxyphenyl (SBDPiR730, SBDPiR731, SBDPiR740) displayed 
enhanced red-shift towards NIR absorption. Interestingly, SBDPiR840 
having 4-N,N-dimethylaminophenyl group as a donor moiety showed a 
large SoS1 transition with the lowest energy, presumably, as a result of 
the intramolecular charge transfer (ICT) imposed by the 
dimethylaminophenyl substituent, which significantly reduced the HOMO-
LUMO gap. 
The fluorescence spectra of these SBDPiRs showed emission in the 
NIR from 660 nm to >800 nm making them similar or better than cyanine 
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dye series which are widely used. The sharp emission bands and almost no 
spectral overlap with its absorption band as observed (Fig. 23) render these 
SBDPiRs akin to available quantum dots.88 In addition, possibility of 
spectral separation puts the SBDPiRs in a potential position for use in 
cellular and in vivo imaging as well as multicolor assays. 
 
 Figure 23. Absorption and emission spectra of 
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Table 5. Optical properties of BDP635 and SBDPiRs 
Dye λabs, nm λflu, nm ε, M-1 cm-1 
BDP 635 650 - 
SBDPiR650_OMe 649 660 118 000 
SBDPiR650 649 660 83 000 
SBDPiR690 688 700 120 000 
SBDPiR700 694 715 105 000 
SBDPiR730 728 761 140 000 
SBDPiR731 731 755 185 000 
SBDPiR735 733 763 125 000 
SBDPiR740 738 763 101 000 
SBDPiR755 753 785 110 000 
SBDPiR790 786 - 85 000 
SBDPiR840 841 - - 
 
 
3.5. In vivo imaging with SBDPiR790 
3.5.1. Materials and Methods 
Female Balb/c mice were purchased from NCI (Federick, MD). Mice 
were housed and handled in the College of Pharmacy animal facility, 
University of Oklahoma Health Sciences Center, Oklahoma City, OK. All 
animal experiments were approved by IACUC, University of Oklahoma 
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Health Science Center (personal approval was offered). Injection solution of 
SBDPiR790 was prepared by solubilizing it in DMSO (4 mM) and then it 
was diluted with 1 % Tween 80 - 5 % dextrose solution (PBS). The solution 
was filtered through a 0.2 µm sterile syringe filter before i.p. injection.  
BALB/c mice bearing colon-26 cells (mouse colon carcinoma cells) 
were used for this study. 6-8 week old Balb/c mice were shaved and 
depilated with hair removal cream (Nair) at the upper back. The mice were 
subcutaneously inoculated with colon 26 cells at the neck region with 1 x 
10-6 cells in 0.1 ml PBS solution. Tumors with 4-6 mm diameter size were 
made in a week. The in vivo Xtreme imaging system (Carestream Health, 
Inc.) was used in acquiring images as mice were kept under safe 
anaesthesia using Isoflurane. The instrumental conditions for the imaging 
were as follows: fluorescence mode with excitation 760 nm and emission 
830 nm; exposure time 5 sec; F/stop: 2 and pixel 2 x 2. Images collected 
were then processed using the Carestream MI imaging software to equally 
adjusted minima and maxima scale. 
 
 Figure 24. Time dependent 
mice bearing colon-26 tumor
 
 
3.5.2. Result and Discussion
All mice received 2.5 µmol/kg of 
solution in PBS (0.2 ml)
15 min, 3, 6, 24 h post
images with time-dependent manner (Fig. 24).
most of the dye still remained in the peritoneal cavity. At 3 h, all skin area 
showed relatively bright emission with intense bright spots in mid
(presumably kidney or peritoneal cavity). At 6 h, most of skin area showed 
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SBDPiR790 (MW=636.11 g/mol)
 via i.p. injection. Images were taken at 0 (before), 
-injection. SBDPiR790 showed relatively clear 
 At 15 min, it seemed the 
 
 in BALB/c 
 
-body 
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some emission but an intense emission was observed in the tumor area. At 
24 h, skin showed lower emission intensity than at 3 and 6 h time points but 
brighter emission was observed at the tumor site than other body. Even 
though more thorough examination is needed, these results clearly 
demonstrated the potential of SBDPiR790 for NIR in vivo optical imaging. 
Particularly SBDPiR790 can be a practical alternative to the sole clinically 
approved NIR probe, ICG. The stability, and excellent photophysical 
properties of SBDPiR790 and its lipophilic character make it useful for 
varied applications including cancer diagnosis and neurological imaging 
taking advantage of its ability to cross the blood-brain barrier. 
 
3.6. Conclusion 
The synthesis of novel NIR BODIPYs, the SBDPiRs, followed a 
rational approach in their design that was carefully executed. In this 
strategy, I designed a building block to be used as an intelligent scaffold of 
which several NIR BODIPY dyes were developed. The building block 
BDP635 was designed and synthesized as a reactive brominated fused 
BODIPY chromophore with absorption in the visible region, λmax = ~635 nm. 
The BODIPY aryl halide was referred to as ‘versatile’ due to its reactivity 
towards various palladium catalyzed coupling partners as well as 
nucleophilic reagents. Using varying coupling partners such as boronic 
acids, organo tin compounds, and arylvinyl molecules, Suzuki, Stille and 
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Heck reactions were successfully performed. Moreover, nucleophiles such 
as substituted phenols and thiophenol worked remarkably well for the 
nucleophilic substitution reactions. Interestingly, the range of NIR dyes 
generated possessed characteristics (sharp absorption and emission and 
high molar extinction coefficient) similar to approved fluorescence dyes with 
an added advantage of flexible tuning to achieve dyes with absorptivity > 
800 nm. In addition, I demonstrated the potential of one of the dyes for in 
vivo optical imaging. I propose this strategy and this class of SBDPiRs for 
use as in vivo imaging probes. These could also be further developed as 
PSs with slight modifications to enhance the intersystem crossing such as 
bromination and iodination. 
 
3.7. Experimental Section 
3.7.1. 2-Bromo-4H-thieno [3, 2-b] pyrrole-5-carboxylic acid (47)*: 46 
(0.30 g, 1.1 mmol) was dissolved in EtOH (10 ml). NaOH (0.62 g, 15.5 
mmol) in water (4.9 ml) was added and refluxed for 1 h. The reaction was 
cooled to room temperature and then chilled in an ice bath to acidify the 
mixture with concentrated HCl. The precipitate was filtered, washed with 
water and dried under vacuum. A grey solid was obtained (0.22 mg, 70 % 
[based on 1H-NMR]). 1H-NMR (DMSO-d6, 300 MHz): δ 12.76 (s, 1H), 12.15 
(s, 1H), 7.21 (s, 1H), 6.99 (s, 1H). HRMS ESI (m/z): Calculated for 
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C7H4BrNO2S: 246.0812; found: 246.0833 [M+H]+. *Known with slight 
modification. 
3.7.2. 2,8-Di(bromo)-11-trifluoromethyl-dithieno[2,3-b]-[3,2-g]-5,5-
difluoro-5-bora-3a,4a-dithio-s-indacene (BDP635): 47 (1.0 g, 1.8 mmol) 
was dissolved in TFA (25 ml) and heated to 40 °C for 1 5 min. An intense 
red color appeared. Trifluoroacetic anhydride (9 ml) was added and the 
temperature was then raised to 80 °C with continued sti rring for 4 h. A deep 
blue color was observed. The reaction solution was allowed to cool and 
poured into an aqueous NaHCO3 solution with crushed ice. The solution 
containing precipitates was then filtered and the solid was dried in vacuo. 
The dry solid was dissolved in CH2Cl2 (250 ml) and stirred for 5 min at room 
temperature under a nitrogen atmosphere. Boron trifluoride dietherate (4 
ml) and triethylamine (3 ml) were added and the reaction was stirred at 
room temperature for 1 h. The reaction solution was passed through a silica 
gel column using CH2Cl2 as eluent. An intense blue solution was obtained 
as pure compound which appeared as a bluish-green metallic solid (160 
mg, 16 % [based on 1H-NMR]). 1H-NMR (CDCl3, 300 MHz): δ 7.31 (s, 2H), 
7.24 (s, 2H). HRMS EI (m/z): Calculated for C14H4BBr2F5N2S2: 529.8200; 
Found: 529.8170[M]+. 
3.7.3. 2,8-Di(4-hydroxyphenyl)-11-trifluoromethyl-dithieno[2,3-b]-[3,2-
g]-5,5-difluoro-5-bora-3a,4a-diaza-s-indacene (SBDPiR740): To a 1:1:1 
toluene/THF/H2O solution of BDP635 (0.19 g, 0.36 mmol) was added 4-
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hydroxyboronic acid (0.20 g, 1.43 mmol) and Na2CO3 (0.11 g 1.05 mmol). 
The reaction solution was purged by bubbling nitrogen gas through for 10 
min. A catalytic amount of Pd(PPh3)4 (~5 mol %) was added and the 
reaction heated to 80 °C for 2 h. After completion of  the reaction as judged 
by TLC, the reaction was diluted with 5 ml water and extracted with diethyl 
ether. The combined organic layer was washed with water and brine and 
dried over anhydrous Na2SO4. The dried mixture was purified by silica-gel 
column chromatography using ethyl acetate – hexane (50:50) as eluent. A 
dark green solid was obtained (102 mg, 54 %, [based on 1H-NMR]). 1H-
NMR (acetone-d6, 300 MHz): δ 7.84 (d, J = 9.0 Hz, 4H), 7.52 (s, 2H), 7.37 
(s, 2H) 7.03 (d, J = 9.0 Hz, 4H). HRMS EI (m/z): Calculated for 
C26H14BF5N2O2S2: 556.0510; Found: 556.0520 [M]+. 
3.7.4. 2,8-Di(4-methoxyphenyl)-11-trifluoromethyl-dithieno[2,3-b]-[3,2-
g]-5,5-difluoro-5-bora-3a,4a-diaza-s-indacene (SBDPiR731): To a 1:1:1 
toluene/THF/H2O solution of BDP635 (0.10 g, 0.2 mmol) was added 4-
methoxyphenylboronic acid (0.12 g, 0.8 mmol) and Na2CO3 (0.06 g 0.6 
mmol). The reaction solution was purged by bubbling nitrogen gas through 
for 10 min. A catalytic amount of Pd(PPh3)4  (~5 mol %) was added and the 
reaction heated to 80 °C for 2 h. After completion of  the reaction as judged 
by TLC, the reaction was diluted with 5 ml water and extracted with diethyl 
ether. The combined organic layer was washed with water and brine and 
dried over anhydrous Na2SO4. The dried mixture was purified by silica-gel 
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column chromatography using ethyl acetate – toluene (5:95) as eluent. A 
dark green solid was obtained (53 mg, 50 % [based on 1H-NMR]). 1H-NMR 
(CD2Cl2, 400 MHz): δ 7.76 (d, J = 8.0 Hz, 4H), 7.34 (s, 2H), 7.32 (s, 2H), 
7.03 (d, J = 8.0 Hz, 4H), 3.91 (s, 6H). HRMS EI (m/z): Calculated for 
C28H18BF5N2O2S2: 584.0823; Found: 584.0825 [M]+. 
3.7.5. 2,8-Di(thiophenyl)-11-trifluoromethyl-dithieno[2,3-b]-[3,2-g]-5,5-
difluoro-5-bora-3a,4a-diaza-s-indacene (SBDPiR735): To a 1:1:1 
toluene/THF/H2O solution of BDP635 (0.10 g, 0.2 mmol) was added 2-
thiopheneboronic acid (0.10 g, 0.8 mmol) and Na2CO3 (0.06 g  0.6 mmol). 
The reaction solution was purged by bubbling nitrogen gas through for 10 
min. A catalytic amount of Pd(PPh3)4  (~5 mol %) was added and the 
reaction heated to 80 °C for 30 min. After completion  of the reaction as 
judged by TLC, the reaction was diluted with 5 ml water and extracted with 
diethyl ether. The combined organic layer was washed with water and brine 
and dried over anhydrous Na2SO4. The dried mixture was purified by silica-
gel column chromatography using ethyl acetate – toluene (5:95) as eluent. 
A dark green solid was obtained (51 mg, 50 % [based on 1H-NMR]). 1H-
NMR (CD2Cl2, 300 MHz): δ 7.24 (m, 2H), 7.53 (s, 2H), 7.54 (s, 2H), 7.34 (s, 
2H), 7.57 (m, 4H). HRMS EI (m/z): Calculated for C22H10BF5N2S4: 
535.9740; Found: 535.9725 [M]+. 
3.7.6. 2,8-Di(3,4,5-trimethoxyphenyl)-11-trifluoromethyl-dithieno[2,3-b]-
[3,2-g]-5,5-difluoro-5-bora-3a,4a-diaza-s-indacene (SBDPiR730): To a 
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1:1:1 toluene/THF/H2O solution of BDP635 (0.12 g, 0.2 mmol) was added 
3,4,5-trimethoxyphenylboronic acid (0.19 g, 0.9 mmol) and Na2CO3 (0.07 g 
0.7 mmol). The reaction solution was purged by bubbling nitrogen gas 
through for 10 min. A catalytic amount of Pd(PPh3)4  (~10 mol %) was 
added and the reaction heated to 80 °C for 1 h. Aft er completion of the 
reaction as judged by TLC, the reaction solution was diluted with 10 ml 
toluene and the water layer separated. The organic layer was washed with 
water and brine and dried over anhydrous Na2SO4. The dried mixture was 
purified by silica-gel column chromatography using ethyl acetate – toluene 
(5:95) as eluent. A dark green solid was obtained (54 mg, 45 % [based on 
1H-NMR]). 1H-NMR (CD2Cl2, 300 MHz): δ 7.36 (s, 2H), 7.32 (s, 2H), 6.98 (s, 
4H), 3.93 (s, 12H), 3.87 (s, 6H). HRMS EI (m/z): Calculated for 
C32H26BF5N2O6S2: 704.1245, Found: 704.1226 [M]+. 
3.7.7. 2,8-Di(4-N,N,dimethylaminophenyl)-11-trifluoromethyl-
dithieno[2,3-b]-[3,2-g]-5,5-difluoro-5-bora-3a,4a-diaza-s-indacene 
(SBDPiR840): To a 1:1:1 toluene/THF/H2O solution of BDP635 (0.12 g, 0.2 
mmol) was added 4-N,N,dimethylaminophenylboronic acid (0.11 g, 0.7 
mmol) and Na2CO3 (0.07 g 0.7 mmol). The reaction solution was purged by 
bubbling nitrogen gas through for 10 min. A catalytic amount of Pd(PPh3)4 
(~10 mol %) was added and the reaction heated to 80 °C for 2 h. After 
completion of the reaction as judged by TLC, the reaction was diluted with 
10 ml toluene and the water layer separated. The organic layer was washed 
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with water and brine and dried over anhydrous Na2SO4. The dried mixture 
was purified by silica-gel column chromatography using toluene as eluent. 
A dark green solid was obtained (24 mg, 20 % [based on 1H-NMR]). 1H-
NMR (CD2Cl2, 300 MHz): δ 7.68 (d, J = 6.0 Hz, 4H), 7.37 (s, 2H), 7.34 (s, 
2H), 7.40 (d, J = 6.0 Hz, 4H), 3.07 (s, 9H), HRMS EI (m/z): Calculated for 
C30H24BF5N4S2: 610.1456, Found: 610.1470 [M]+. 
3.7.8. 2,8-Di(styryl)-11-trifluoromethyl-dithieno[2,3-b]-[3,2-g]-5,5-
difluoro-5-bora-3a,4a-diaza-s-indacene (SBDPiR755): In a one-neck 
flask BDP635 (0.08 g, 0.2 mmol), styrene (0.04 g, 0.4 mmol), Pd(OAc)2 (20 
mol %), triphenylphosphine (20 mol %), Na2CO3 (0.06 g 0.6 mmol) were 
dissolved in anhydrous toluene (3 ml). The reaction solution was heated to 
80 °C with stirring under N 2 (g) for 6 h. After completion (monitored by TLC) 
the reaction was diluted with 10 ml toluene and washed with water and 
brine and dried over anhydrous Na2SO4. The dried mixture was purified by 
silica-gel column chromatography using toluene as eluent. A black solid 
was obtained (17 mg, 22 % [based on 1H-NMR]). 1H-NMR (CD2Cl2, 300 
MHz): δ 7.59 (d, J = 8.0 Hz, 4H), 7.39 (d, J = 8.0 Hz, 4H), 7.26 (s, 3H), 7.20 
(s, 1H), 7.12 (s, 2H). HRMS EI (m/z): Calculated for C30H18BF5N2S2: 
576.0925; Found: 576.0906 [M]+. 
3.7.9. 2,8-Di(4-(methoxy-phenyl)vinyl)-11-trifluoromethyl-dithieno[2,3-
b]-[3,2-g]-5,5-difluoro-5-bora-3a,4a-diaza-s-indacene (SBDPiR790): In a 
one-neck flask BDP635 (0.08 g, 0.2 mmol), 4-methoxystyrene (0.04 g, 0.4 
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mmol), Pd(OAc)2 (20 mol %), triphenylphosphine (20 mol %), Na2CO3 (0.06 
g 0.6mmol) were dissolved in anhydrous toluene (3 ml). The reaction 
solution was heated to 80 °C with stirring under N 2 (g) for 6 h. After 
completion (monitored by TLC) the reaction was diluted with 10 ml toluene 
and washed with water and brine and dried over anhydrous Na2SO4. The 
dried mixture was purified by silica-gel column chromatography using 
toluene as eluent. A dark brown solid was obtained (20 mg, 25 % [based on 
1H-NMR]). 1H-NMR (CD2Cl2, 300 MHz): δ 7.44 (d, J = 9.0 Hz, 4H), 7.17 (s, 
2H), 7.16 (s, 2H), 7.15 (s, 2H), 6.99 (s, 2H), 6.88 (d, J = 9.0 Hz, 4H). HRMS 
EI (m/z): Calculated for C32H22BF5N2O2S2: 636.1136; Found: 636.1120 [M]+. 
3.7.10. 2,8-Di(phenyl)-11-trifluoromethyl-dithieno[2,3-b]-[3,2-g]-5,5-
difluoro-5-bora-3a,4a-diaza-s-indacene (SBDPiR690): In a one-neck 
flask BDP635 (0.03 g, 0.1 mmol), tetraphenyltin (0.03 g, 0.1 mmol), 
Pd(OAc)2 (20 mol %), triphenylphosphine (20 mol %), Na2CO3 (2 ml, 1 M 
aq.) were dissolved in toluene (3 ml). The reaction solution was heated to 
80 °C with stirring under N 2 (g) for 1 h. After completion (monitored by TLC) 
the reaction was diluted with 10 ml toluene and washed with water and 
brine and dried over anhydrous Na2SO4. The dried mixture was purified by 
silica-gel column chromatography using toluene as eluent. A green solid 
was obtained (10 mg, 30 % [based on 1H-NMR]). 1H-NMR (CD2Cl2, 300 
MHz): δ 7.52 (d, J = 8.0 Hz, 4H), 7.40 (s, 2H), 7.31 (peaks overlap, 6H), 
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7.24 (s, 2H). HRMS EI (m/z): Calculated for C26H14BF5N2S2: 524.0612; 
Found: 524.0599 [M]+. 
3.7.11. 2,8-Di(thiophenoxy)-11-trifluoromethyl-dithieno[2,3-b]-[3,2-g]-
5,5-difluoro-5-bora-3a,4a-diaza-s-indacene (SBDPiR700): BDP635 (0.03 
g, 0.06 mmol), thiophenol (0.02 g, 0.14 mmol), and K2CO3 (0.02 g, 0.14 
mmol) were dissolved in anhydrous CH3CN (3 ml). The reaction solution 
was heated to 80 °C with stirring under N 2 (g) for 30 min, the reaction turns 
brick red. After completion (monitored by TLC) the reaction was diluted with 
10 ml ether and washed with 1 M Na2CO3 (aq.) and dried over anhydrous 
Na2SO4. The dried mixture was purified by silica-gel column 
chromatography using toluene as eluent. A green solid was obtained (10 
mg, 30 % [based on 1H-NMR]). 1H-NMR (CD2Cl2, 300 MHz): δ 7.62 (d, J = 
6.0 Hz, 4H), 7.47 (d, J = 6.0 Hz, 4H), 7.24 (s, 2H), 7.15 (s, 2H), 6.91 (s, 2H). 
HRMS EI (m/z): Calculated for C26H14BF5N2S4: 588.0053; Found: 588.0037 
[M]+. 
3.7.12. 2,8-Di(4-methoxyphenoxy)-11-trifluoromethyl-dithieno[2,3-b]-
[3,2-g]-5,5-difluoro-5-bora-3a,4a-diaza-s-indacene (SBDPiR650_OMe): 
BDP635 (0.06 g, 0.1 mmol), 4-methoxyphenol (0.06 g, 0.3 mmol), and 
K2CO3 (0.05 g, 0.4 mmol) were dissolved in anhydrous CH3CN (3 ml). The 
reaction solution was heated to 80 °C with stirring un der N2 (g) for 30 min. 
After completion (monitored by TLC) the reaction was dried, dissolved in 
CH2Cl2 and washed with water and brine and dried over anhydrous 
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Na2SO4. The dried mixture was purified by silica-gel column 
chromatography using hexane as eluent. A blue solid was obtained (15 mg, 
25 %, [based on 1H-NMR]). 1H-NMR (CD2Cl2, 300 MHz): δ 7.09 (d, J = 8.0 
Hz, 4H) 7.00 (s, 2H), 6.85 (d, J = 8.0 Hz, 4H), 6.21 (s, 2H), 3.77 (s, 6H). 
HRMS EI (m/z): Calculated for C28H18BF5N2O4S2: 616.0721; Found: 
616.0724 [M]+. 
3.7.13. 2,8-Di(biphenyl-4-yloxy)-11-trifluoromethyl-dithieno[2,3-b]-[3,2-
g]-5,5-difluoro-5-bora-3a,4a-diaza-s-indacene (SBDPiR650): BDP635 
(0.06 g, 0.1 mmol), 4-phenylphenol (0.06 g, 0.3 mmol), and K2CO3 (0.05 g, 
0.4 mmol) were dissolved in anhydrous CH3CN (3 ml). The reaction solution 
was heated to 80 °C with stirring under N 2 (g) for 30 min. After completion 
(monitored by TLC) the reaction was diluted with 10 ml toluene and washed 
with water and brine and dried over anhydrous Na2SO4. The dried mixture 
was purified by silica-gel column chromatography using ethyl acetate – 
hexane (50:50) as eluent. A reddish-brown solid was obtained (42 mg, 70 
% [based on 1H-NMR]). 1H-NMR (CDCl3, 300 MHz): δ 7.52 (m, 3H), 7.49 
(m, 5H) 7.43 (m, 5H), 7.30 (d, J = 9.0 Hz, 3H), 7.20 (s, 1H), 6.80 (d, J = 9.0 
Hz, 2H), 6.39 (s, 1H). HRMS EI (m/z): Calculated for C38H22BF5N2O2S2: 
708.1136; Found: 708.1121 [M]+. 
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Chapter 4 
Functionalization of NIR BODIPY and Biological Evaluation  
 
4.0. Introduction 
Generally, targeted therapies are developed to reduce side effects. 
For example, the side effects associated with conventional cancer 
chemotherapy can be reduced by molecular-targeted cancer therapy.89 The 
use of molecular probes and photonic agents for in vivo therapy requires 
high selectivity or specificity to the diseased site. Although second 
generation fluorescent probes and PDT agents relied on passive targeting 
of tumor vasculature, not all diseased locations can take advantage of this 
targeting approach. Moreover, destruction of central tumor vasculature by 
some second generation PS though effective cannot be used for peripheral 
vasculature. Active targeting became a useful tool to enhance target 
specificity. Active targeting involves the covalent conjugation of probes to 
targeting vectors such as ligands, peptides and antibodies to improve the 
affinity of these probes to target sites based on corresponding receptors or 
antigens. Among the several targeted therapies the use of monoclonal 
antibodies (mAb) has received greatest attention with the FDA approval of 
~25 mAb therapeutics.90, 91  
The conjugation of these targeting biomolecules to PSs or fluorescent 
probes requires appropriate functional groups on the PS/probes. The 
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challenges with most NIR absorbing chromophores are high hydrophobicity 
and limited potential for functionalization. In this chapter, I attempted the 
functionalization of NIR BODIPYs by 1) meso-functionalized approach and 
2) extended functionalization from a modified BODIPY core. 
Among the BODIPY analogs, SBDPiR715 showed excellent 
photophysical properties, balanced fluorescence emission and effective 
singlet oxygen generation, as a dual functioning PS for theranostic 
application (PDD guided PDT). Thus, I performed pilot in vivo studies with 
SBDPiR715 to gauge its potential for dual-functioning PS. Indeed, 
SBDPiR715 showed bright in vivo images and ablation of large tumors. 
However, since it is highly lipophilic and planar to readily form aggregates, I 
functionalized SBDPiR715 with carboxylic acid moieties to increase water 
solubility and reduce the aggregation tendency. The di-carboxyl group 
functionalized SBDPiR715 can also be used for further modifications such 
as conjugation to delivery vectors via an ester bond.  
 
4.1. Synthesis of Meso-Functionalized NIR BODIPY, 50 
The meso-functionalized NIR BODIPY was designed by adding a 
carboxy phenyl group at the meso position of the thiophene-fused BODIPY 
core (50, Scheme 7). I hypothesized that it would form D-π-A system where 
4-methoxyphenyl fragments act as donor moieties to push electrons 
through the highly conjugated fused BODIPY framework to the carboxy 
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phenyl group (an acceptor). The synthesis utilized previous approach to 
build a modified fused pyrrole substrate (Scheme 1). The pyrrole substrate 
47 was decarboxylated under thermal, copper catalyzed conditions to 
obtain free pyrrole at the 2-position. Mono methyl-terephthalate 49 was 
activated using thionyl chloride to generate a reactive electrophile for 
condensation with the modified free pyrrole. A subsequent boron chelation 
step was performed which afforded the target compound 50.  
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Scheme 7. Synthetic approach for meso-functionalized NIR BODIPY 
 
4.2. Results and Discussion 
4.2.1. Synthesis 
The synthesis of compound 50 required the preparation of the 
pyrrole intermediate 48 (scheme 7). The methoxyphenylthienopyrrole, 48 is 
a new compound and quite challenging to make it in respectable yields. A 
basic decarboxylation approach using NaOH in ethylene glycol as well as 
acid promoted decarboxylation with TFA generated very low yields (<10 %). 
Other decarboxylation methods such as transition-metal catalyzed 
decarboxylation often used for phenyl-substituted carboxylic acids proved 
87 
 
unsuccessful. However, the use of doubly distilled quinoline and copper (I) 
oxide at high temperatures of 220 °C as reported in l iterature92 obtained an 
improved yield of 40 %. The compound was carefully handled as it was 
exposed to minimal amount of light. The purification was done using a 
modified (1 % TEA) silica-gel column chromatography. The final 
functionalized BODIPY bearing a phenyl carboxylate at the meso-position 
was achieved by using the reactive 4-chlorocarbonyl-benzoic acid methyl 
ester (49) and the heterocycle (48). The reaction followed a synthetic 
protocol used by Burgess et al. giving similar reaction yields (3 %).46 
 
4.2.2. Optical properties 
The solution of 50 in CHCl3 gave a vivid bluish-green color. The 
observation was an account of a strong 0-0 absorption at 685 nm. The 
molar extinction coefficient was remarkably lower (85 000 M-1cm-1) than the 
CF3 meso substituted analogues (~200 000 M-1cm-1). That could be 
attributed to the free rotation of the phenyl carboxylate ring at the meso-
position to the fluorophore that broke the planarity of the structure. In 
addition, the free rotation accounts for the relatively low fluorescence. 
 Figure 25. Optical spectra of Meso
 
4.2.3. Theoretical insight
Geometry optimization was performed using the Spartan
computational suite. 
empirical model in vacuo was utilized. 
reasoned, localized at the donor region, methoxyphenyl group in the 
HOMO. The effect of the acceptor, phenylcarboxylate, though sho
electron pull may be relatively 
absorption wavelength at 685 nm in solution as a result of relatively lo
HOMO – LUMO band
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The single point energy optimization with a PM3 semi
I observed the electron density as 
weak. That may account for the shorter 
 gap. 
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 Figure 26. Geometry optimization
 
 
4.3. Di-carboxylic acid 
The di-carboxylic acid analog 
solubility and to reduce aggregation tendency of highly planar compound.
addition, the carboxylic acid groups could be used for the conjugation to 
delivery vectors or delivery vehicles.
group tolerance of the Suzuki coupling to attach hydroxyl groups as 
evidenced in SBDPiR740
substitution reaction with ethylbromoacetate. To 
dye 51 to dual functioning PS 
synthesis was completed by basic hydrolysis of the ester groups 
obtain free carboxylic acids
89 
 of meso-functionalized NIR BODIPY, 
Functionalized SBDPiR 
53 was designed to improve water 
 I took advantage of the functional 
 (Scheme 8). I furthermore performed a 
transform the fluorescence 
52, the BODIPY core was brominated
 of 53. 
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Scheme 8. Synthesis of functionalized NIR BODIPY, 53  
 
4.4. Results and Discussion 
4.4.1. Synthesis  
Generating di-carboxylic acid functionalized NIR BODIPY needed a 
starting material with a functional group. From the earlier synthesis of the 
SBDPiRs, I used SBDPiR740 as the starting point, taking advantage of its 
hydroxyl groups (Scheme 3). I performed O-alkylation via a nucleophilic 
substitution reaction with ethylbromoacetate in acetonitrile under reflux 
conditions for 16 h. Surprisingly, acetone did not work as a solvent for the 
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BODIPY substrate in the current work. I strategically carried out an 
electrophilic bromination via the established methodology (Scheme 1 in 
Chapter 2) using bromine and trace iodine in DCM under reflux. The 
bromination was done before the final step to avoid any interfering reactions 
with the carboxylic acids of 53. Basic hydrolysis with 0.2 N NaOH (aq.) in a 
mixture of THF/MeOH with subsequent reflux afforded the final compound 
53 in good yield (60 %). The carboxylic acids at the periphery are platforms 
for conjugation to targeting vectors. All compounds were purified by silica-
gel column chromatography with the exception of 53 (precipitated after 
acidification) and were characterized by 1H-NMR and EI-HRMS. 
 
4.4.2. Singlet oxygen generation and Photostability. 
A singlet oxygen generation experiment on 53 using the indirect 
method of DPBF photooxidation was performed. There were strong 
similarities of the behavior of 53 towards DPBF with 41. In addition, the 
photostability of 53 showed relatively better than the clinically approved m-
THPC (Foscan). It was established that the functionalization of these novel 
PSs do not affect their excellent photophysical behavior (Fig. 26). The 
photooxidation of DPBF was monitored by UV-vis spectrophotometer at 410 
nm. Within 20 min the oxidation rate compared to that of 41, indicating that 
compound 53 is also a potent singlet oxygen generator despite the 
functionalization. Additionally, less than 30 % of 53 photobleached under 
 the harsh light illumination condition over a period of an hour, which is a 
strong evidence for photostability.
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 Figure 27. Comparative SO generation by DPBF
 
4.5. In Vivo Optical 
Optical imaging was performed with an IVIS Spectrum small
in vivo imaging system (Caliper LS). The Living Image Software v3.0 
(Caliper LS) was used to analyze images and measurements of fluorescent 
signals. Excitation and emission wavelengths of 720
respectively were 
(M.W=830.20 g/mol).
and an f/stop of 1, with a sampling of multiple angles with animal under 
Isoflurane anaesthesia. Animals 
53 via i.p. administration. 
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 (A) and Photostability
imaging with 53 
 nm and 760
used to acquire in vivo fluorescent images of 
 All images were attained using a 1-s exposure time 
were injected with 2.5 µmol/kg 
 
 (B) 
-animal 
 nm, 
53 
(2 mg/kg) of 
 Figure 28. Time-dependant fluorescent images of 53 in nude mouse (from 
top left: (A) 0, (B) 5, 
 
The in vivo imaging study 
imaging probe. Bright fluorescence signal was detected from mouse (Fig. 
27). At 5 and 10 min, two bright areas were observed in the mid
presumably, due to the PS in peritoneal cavity before absorption to the 
system (blood). At 3 and 6 h, most skin showed bright emi
clear bright spots also observed, probably kidneys. At 12 hr, the intensity of 
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(C) 10 min, (D) 3, (E) 6, (F)12 h after i.p. injection)
of 53 proved its potential as an in vivo
ssion and two 
 
 
 optical 
-body, 
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skin was lower than 3 and 6 h images. Most of 53 might be cleared out from 
the system.  
 
4.6. In Vivo Drug Biodistribution and PDT of 41  
4.6.1. Materials and Methods 
4.6.1.1. PS 
To obtain an injection solution of 41, the emulsifier Tween 80 was 
used. Tween 80 is a nonionic surfactant, frequently used in vivo as 
solubilizing agent for highly lipophilic therapeutics. The formulation 
procedure required dissolving the PS in a minimal amount of Tween 80 
(100 µl). The paste was allowed to stand overnight. 5% Dextrose in 
phosphate-buffered saline (PBS) solution was added and the solution was 
sonicated for 1 h. The resulting green solution was filtered through a 0.2 µm 
membrane filter. To ensure the accuracy of the concentration, which might 
vary due to partial solubility of the PS, the exact concentration was 
confirmed by UV-visible spectral analysis of the solutions prior to dosing. 
 
4.6.1.2. Cells 
Colon-26 mouse carcinoma cells were obtained from the American 
Type Culture Collection (ATCC) and cultured in minimum essential medium 
supplemented with 10% (v/v) fetal calf serum (FCS), 50 U ml-1 penicillin, 50 
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µg ml-1 streptomycin and 1% (v/v) L-glutamine. The cells were maintained 
in 5% CO2 (v/v) and 21% O2 (v/v) at 37oC.  
 
 
4.6.1.3. Animal Models 
All animal experiments were approved by IACUC of the University of 
Oklahoma Health Science Center. Female BALB/c mice were received 
purchased from Charles River at 6–8 week old. Balb/c mice were shaved 
on the upper back and depilated with Nair (Carter-Wallace Inc., New York, 
NY, USA). Mice were anesthetized with an i.p. injection of 
ketamine/xylazine cocktail (90 mg kg-1 ketamine and 10 mg kg-1 xylazine). 
One million colon-26 cells were injected subcutaneously in one dorsal neck 
area suspended in 100 ml PBS. Tumors grew predictably in all the mice 
and reached a size of 4- to 6-mm diameter in 5–7 days or 8 – 11 mm in 14 
– 16 days after injection, at which time they were used for PDT.  
 
4.6.1.4. Drug efficacy studies: PDT Protocol 
Compound 41 in 1% Tween 80 - 5% Dextrose solvent was injected 
i.p. at a dose of 3 µmol/kg (2.2 mg/kg) and 5 µmol/kg (3.7 mg/kg) in 0.2 ml 
solution. Tumors were irradiated 6 h, 24 h or 32 h after the injection using a 
Lumacare LC-122M with a fiber-optic light delivery system (Lumacare, 
Newport Beach, CA, USA) emitting light at 700 nm (±40 nm). The 
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illuminating spot had a diameter of 1.2 cm and was positioned so that the 
entire tumor and a surrounding 2–3 mm area of normal tissue were 
exposed to light. No evident temperature increase was detected at the site 
of irradiation. Mice were anesthetized as described above and the tumor-
bearing limb positioned under the spot. Total dose of 200 – 300 mW/cm2 
was delivered for 30 min (360 – 540 J cm-2).  Mice bearing colon-26 tumors 
were also irradiated without having received injection of 41. Another group 
of animals was treated with 41 i.p. without irradiation. After irradiation, mice 
were allowed to recover in an animal cotton blanket until they resumed 
normal activity. A positive tumor response was ascribed to tumors that 
appeared flat blackened or reddened scarp and necrotic tissue within a few 
days after PDT. Animals were considered cured after complete tumor 
regression and the absence of a palpable tumor. 
A mass tumor necrosis was observable after a few hours – a day 
following PDT treatment with the development of necrosis and eschar. 
Tumor healing however took ~30 days with remodeling of the damaged or 
scarred tissue. The protocol treated larger tumors (8 - 11 mm diameter) that 
are rarely used pre-clinically. No weight loss or other visual signs of toxicity 
was observed at the treatment dose of 5 µmol/kg (3.7 mg/kg). There was no 
effect on the group treated with light alone. 
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4.6.1.5. Drug biodistribution  
Mice were injected via i.p. with 41 (5 µmol/kg/3.7 mg/kg). After 24 h 
postinjection, the mice (n=3) were euthanized by CO2 inhalation. Tissues 
were excised from major organs and tumor. Collected tissues were rinsed 
with PBS and blotted dry. One hundred milligram of excised tissue was 
homogenized with CHCl3 (1 ml). The homogenates were centrifuged at 
5160 g for 20 min and the supernatant used for fluorescence measurement 
(excitation at 710 nm and emission at 754 nm). The amount of compound in 
each sample was evaluated relative to the standard curve and expressed in 
‘‘mg/g of tissue’’ unit. 
 
4.7. Results and Discussion 
Compound 41-mediated PDT studies demonstrated under varying 
drug-light interval of 6 h (n = 3), 24 h (n = 4) and 32 h (n = 3) respectively 
(Fig. 28) has shown to be an exciting new class of phototherapeutic agent, 
possessing significant potential for preclinical development. The in vivo 
response to 41 PDT used the colon 26 tumor bearing mice to determine 
drug-light combination tolerance. I employed two approaches in the 
treatment; 1) traditional PDT protocol frequently used in our lab with a 24 h 
drug-light interval with a starting tumor size of ~85 mm3. 2) Treatment of 
larger tumor sizes (~650 mm3) with 6 h and 32 h drug-light interval for 
preferential drug accumulation at the tumor site.  
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Within 3 weeks control groups of tumor alone (control, n = 4) and tumor with 
24 h drug-light interval (light only, n = 3) reached high tumor volumes at 
consistent rates. In the same period the treatment groups experienced 
mass necrosis and eschar within a day. For the 6 and 24 h drug-light 
interval treatment groups, the observed necrosis spread to neighboring skin 
regions probably due to 41 in the skin causing skin photosensitization (Fig. 
29 and Fig. 30). In the 32 h treatment group there seemed to be a 
preferential accumulation of the drug in the tumor region leading to a 
confinement of necrosis to the tumor region (Fig. 31). All the treatment 
groups showed complete tumor ablation as monitored for 90 days.  
In this study I showed compound 41 was well tolerated with high 
efficacy in vivo employing short to long drug-light intervals. The observed 
cure in the colon 26 bearing tumor model and in two treatment groups 
larger than clinical tumor sizes is encouraging. In addition, the in vivo 
response compares to the well established aza-BODIPY, ADPM06,93 for 
preclinical indication as well as the vascular targeting TOOKAD developed 
in 2002 and in current clinical trials for prostate cancer.94 Compound 41-
mediated PDT showed promise as a useful lead candidate with properties 
as an ideal second generation PS such as high extinction coefficient 
(89,000 M-1cm-1), good fluorescence property (BT = 40,050 M-1cm-1) 
valuable for imaging. The dual functioning ability of compound 41 as a 
diagnostic and therapeutic agent and its high photostability places it ahead 
 of almost all the clinically approved agents such as Photofrin 
1,170 M-1cm-1), a non
1cm-1) in current clinical use
demonstrated the use of compound 
larger tumors of volume ~650 mm
The hydrophobic nature of 
biological systems may be delayed. Approaches to functionalize compound 
41 with water solubilizing groups such as carboxylic acids, sulfonate groups 
may be a useful venture.
 
 
Figure 29. In vivo response to Compound 
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Figure 31. In vivo response to 
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Figure 32. In vivo response to 
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I also showed
consistent with a wide range of 
41 enabled its biodistribution in various organs after systemic delivery 
intraperitoneally. In the biodistribution study, 
accumulation of 41 
result of the general knowledge of hydroph
organism through the bile
content of LDL receptors in the liver, spleen and kidney m
result as 41 is hydrophobic. 
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4.8. Conclusion 
In this chapter, I demonstrated the ability to functionalize the NIR 
BODIPY by facile synthetic methods without compromising the excellent 
photophysical properties they possess. I performed meso-functionalization 
on the thieno fused BODIPY core to obtain compound 50. Its optical 
properties after characterization looked great but suffered from a low yield 
from the condensation step. Furthermore, I show the biological applicability 
of these NIR dyes in vivo; both as an imaging agent and as therapeutic 
agent. Compound 41 showed severe necrosis and extreme tumor ablation 
with high cure rates monitored over a 90 day period. Compound 41 and its 
functionalized form, 53 possess an inherent fluorescent ability useful for 
dual application of diagnosis and therapy. Based on the study I propose 41 
as a viable theranostic candidate for tumor visualization (diagnosis) and 
treatment (therapy). 
 
4.9. Experimental Section 
4.9.1. 2-(4-Methoxy-phenyl)-4H-thieno[3,2-b]pyrrole (48): 2-(4-Methoxy-
phenyl)-4H-thieno[3,2-b]pyrrole-5-carboxylic acid (0.50 g, 1.8 mmol), Cu 
powder (0.18 g, 1.3 mmol) was dissolved in doubly distilled quinoline (10 
ml) and refluxed at 220 °C for 3 h. The reaction mix ture was cooled to room 
temperature and the copper filtered out. The filtrate was poured into cold 
water and acidified with 2 N HCl to pH 4. The solution was extracted with 
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ethyl acetate, washed with 10 % HCl, 10 % NaHCO3, brine and water. The 
solution was dried over anhydrous Na2SO4 and evaporated to dryness. The 
mixture was purified by silica-gel column modified with 1 % triethylamine 
using CH2Cl2 as eluent to afford a yellowish-grey solid (164 mg, 40 % 
[based on 1H-NMR]). 1H-NMR (CD2Cl2, 300 MHz): δ 8.5 (bs, 1H), 7.57 (d, J 
= 9.0 Hz, 2H), 7.18 (s, 1H), 6.87 (d, J = 9.0 Hz, 2H), 3.89 (s, 3H) HRMS EI 
(m/z): Calculated for C13H11NOS: 229.0561; found: 229.0532 [M]+ 
4.9.2. 4-Chlorocarbonyl-benzoic acid methyl ester (49)*:96 Terephthalic 
acid monomethyl ester (0.25 g, 1.4 mmol) was dissolved in thionyl chloride 
(5 ml) and refluxed for 1 h. Excess thionyl chloride was removed in vacuo to 
give an off-white solid. The solid was dissolved in anhydrous benzene (7 
ml) and the solvent evaporated. The procedure was repeated 3 times and 
the solid dried at high temperatures to remove residual solvent. 273 mg was 
obtained at 93 % yield. *Known 
4.9.3. 2,8-Di(4-Methoxy-phenyl)-11-benzoic acid methyl ester-
dithieno[2,3-b]-[3,2-g]-5,5-difluoro-5-bora-3a,4a-diaza-s-indacene (50): 
48 (0.16 g, 0.7 mmol) and 49 (0.07 g, 0.4 mmol) were dissolved in 1,2-
dichloroethane and the solution was refluxed for 72 h. The solution was 
cooled to room temperature and TEA and boron trifluoride etherate was 
added. The mixture was refluxed for 30 min. under He (g) atmosphere. The 
solution was washed with water and brine and the residue was purified by 
silica-gel column chromatography using ethyl acetate – toluene (5:95) as 
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eluent. A green solid was obtained (5 mg, 3%, [based on 1H-NMR]). 1H-
NMR (CDCl3, 300 MHz): δ 8.12 (d, J = 9.0 Hz, 2H), 7.60 (d, J = 9.0 Hz, 4H), 
7.44 (d, J = 9.0 Hz, 2H), 7.41 (s, 2H), 6.88 (d, J = 9.0 Hz, 4H), 6.67 (s, 2H), 
3.80 (s, 3H), 3.92 (s, 6H). HRMS EI (m/z): Calculated for C35H25BF2N2O4S2: 
650.1317; found: 650.1321 [M]+. 
 
4.9.4. 2,8-Di(4-Ethoxycarbonylmethoxy-phenyl)-11-trifluoromethyl-
dithieno[2,3-b]-[3,2-g]-5,5-difluoro-5-bora-3a,4a-diaza-s-indacene (51): 
SBDPiR740 (0.10 g, 0.2 mmol), ethylbromoacetate (0.12 g, 0.7 mmol) and 
K2CO3 (0.05, 0.4 mmol) were dissolved in anhydrous CH3CN under N2 
atmosphere. The solution was heated at 80 °C for 16 h.  After the complete 
consumption of the starting material (monitored by TLC), the reaction was 
stopped. The solvent was removed and the residue was dissolved in 
CH2Cl2. The resulting solution was washed with water and dried over 
anhydrous Na2SO4. The mixture was purified by recrystallization from ethyl 
acetate/cyclohexane mixture to afford a green solid (91 mg, 70 % [based on 
1H-NMR]). 1H-NMR (CDCl3, 300 MHz) :  7.67(d, J = 9.0 Hz, 4H), 7.48 (s, 
2H), 7.32 (s, 2H), 6.97 (d, J = 9.0 Hz, 4H), 4.70 (s, 4H), 4.27 (q, J = 7.1 Hz, 
4H), 1.30 (t, J = 7.1 Hz, 6H)  HRMS EI (m/z): Calculated for 
C34H24BBr2F5N2O6S2: 728.1245; found: 728.1227 [M]+ 
4.9.5. 3,7-Dibromo-2,8-di(4-Ethoxycarbonylmethoxy-phenyl)-11-
trifluoromethyl-dithieno[2,3-b]-[3,2-g]-5,5-difluoro-5-bora-3a,4a-diaza-
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s-indacene (52): 51 (0.07 g, 0.1 mmol) along with I2 (0.001 g) was 
dissolved in CH2Cl2 (15 ml). A solution of Br2 (0.04 g, 0.3 mmol) in CH2Cl2 
(5 ml)
 
was added dropwise and stirred at 40 °C for 12 h. The reaction 
mixture was neutralized with aqueous Na2CO3 solution and the aqueous 
layer was separated from the organic layer. The aqueous layer was further 
extracted with diethyl ether and the combined organic layers were dried 
over anhydrous Na2SO4 and the solvents removed by evaporation to obtain 
a brown solid (40 mg, 52 % [based on 1H-NMR]). 1H-NMR (CD2Cl2, 300 
MHz) :  7.73 (d,  J = 9.0 Hz, 4H), 7.40 (s, 2H), 7.01 (d, J = 9.0 Hz, 4H), 
4.70 (s, 4H), 4.25 (q, J = 7.1 Hz, 4H), 1.30 (t, J = 7.1 Hz, 6H)  HRMS EI 
(m/z): Calculated for C34H24BBr2F5N2O6S2: 885.9435; found: 885.9419 [M]+. 
4.9.6. 3,7-Dibromo-2,8-di(4-Carboxymethoxy-phenyl)-11-
trifluoromethyl-dithieno[2,3-b]-[3,2-g]-5,5-difluoro-5-bora-3a,4a-diaza-
s-indacene (53): 52 (0.04 g, 0.04 mmol) was dissolved in a 1:1 mixture of 
THF/MeOH and 0.4 N NaOH (aq.) was added. The reaction was refluxed 
for 2 h. The THF/MeOH was removed under vacuum and diluted with water 
and acidified with 1N HCl. The precipitate was filtered and dried (23 mg, 63 
% [based on 1H-NMR]). 1H-NMR (CD2Cl2, 300 MHz) : 7.73 (d, J = 9.0 Hz, 
4H), 7.40 (s, 2H), 7.01 (d, J = 9.0 Hz, 4H), 4.70 (s, 4H) HRMS EI (m/z): 
Calculated for C34H24BBr2F5N2O6S2: 829.8809; found: 829.8819 [M]+. 
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Chapter 5  
Conclusion and Perspective 
 
The non-invasive diagnosis and therapy of disease indications with 
light is an emerging modality. In vivo preclinical and clinical applications 
underscore the usefulness of fluorescence imaging and PDT in establishing 
reliable prognosis and disease treatment, particularly for cancer and other 
malignancies. To further the course of these modalities efficient NIR 
absorbing fluorophores and PSs are needed. More specifically, dyes 
absorbing >700 nm with inherent excellent photophysical properties is a 
requisite. These properties should include: 1) high photostability, 2) sharp 
absorption and emission bands, 3) high molar extinction coefficient, 4) 
appreciable fluorescence quantum yield/ singlet oxygen quantum yield, and 
5) potential for functionalization. Since current clinically approved PSs for 
PDT lack absorption in the region >700 nm and only one NIR fluorescence 
dye is FDA approved, it is obvious that the search for efficient, NIR PS and 
alternative NIR fluorophores is a necessity. 
 
In this dissertation, I focused mainly on the design and synthesis of 
NIR BODIPY dyes to: 1) provide improved photodynamic response and 2) 
generate efficient fluorophores for fluorescence imaging. I took advantage 
of ring fusion to the BODIPY core as a unique synthetic strategy as well as 
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D-π-A systems and the incorporation of heavy atoms such as, sulfur, and 
bromine to establish unprecedented longer wavelength dyes in these 
BODIPY analogues. The established synthetic protocol is robust and 
versatile, offering a facile and flexible approach to customizable NIR 
BODIPYs for variegated research. The biological function of these novel 
classes of NIR BODIPY was explored for in vivo photodynamic response to 
ablate tumors and in vivo optical imaging for monitoring and diagnosis. 
 
In the first part of this dissertation, I demonstrated that fusing of a 
thiophene fragment to the BODIPY core as well as electrophilic substitution 
with bromine would induce intersystem crossing leading to singlet oxygen 
generation as well as impart red shift towards NIR. I successfully built the 
thieno-fused BODIPY unit following the D-π-A system along with its furo-
fused analogues and additionally incorporated the bromine atoms for singlet 
oxygen generation. All the analogues showed strong absorption in the NIR 
from 720 – 766 nm in CHCl3 and strong emission of 738 – 820 nm. The 
sulfur containing analogues showed appreciable singlet oxygen generation 
comparable to the core-modified porphyrins, which is a well studied class of 
chromophores in our research group. Photobleaching kinetics showed the 
high photostability of these NIR BODIPYs in comparison to m-THPC 
(clinically approved PDT agent) and its NIR analogue m-THPBC. In this 
work, a lead candidate was obtained with appreciable fluorescence 
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quantum yield. I therefore, propose the candidate as a dual-functional agent 
for PDT and diagnosis or better still for fluorescence-guided PDT.  
 
Secondly, I aimed at developing NIR fluorescent probes and PDT 
agents with a propensity towards functionalization. The search led to the 
design of a robust but versatile synthetic procedure relying on the synthesis 
of a BODIPY alkyl halide absorbing in the visible region and reactive 
towards nucleophilic substitution and transition-metal catalyzed chemical 
transformation with aryl moieties. I successfully synthesized the SBDPiRs 
with sterling optical absorption in the NIR from 650 – 840 nm. I used the 
nucleophilic substitution of substituted phenols and thiophenols to generate 
SBDPiRs with excitability 650 – 700 nm. Suzuki and Stille coupling was 
used to generate SBDPiRs with excitability 688 – 740 nm and the Heck 
coupling was used to obtain SBDPiRs with 755 – 786 nm excitability. The 
study indicated a viable alternative to the cynanines and phthalocynines 
with the NIR absorption and high molar extinction coefficient of the 
SBDPiRs. 
 
Finally, I demonstrated the functionalization of these NIR BODIPY 
and their biological application as photodynamic agents and fluorescence 
imaging probes. I synthesized functional NIR BODIPY fluorophore bearing 
a carboxylate moiety at the meso-position in mimicking the D-π-A system 
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(compound 50). In addition, a PDT agent bearing free-carboxylic acid units 
was synthesized and its potential for in vivo imaging was explored using 
Balb/c mice at a therapeutic dose of 2.5 µmol/kg (2 mg/kg). The drug 
biodistribution of a lead candidate was performed and this established the 
lipophilic nature of the drug as localization in the skin was higher relative to 
the tumor after 24 h. I used an established PDT protocol to show complete 
tumor ablation with varying drug-light interval after intra-peritoneal delivery 
of drug. A 6 h and 24 h drug-light interval showed skin phototoxicity while a 
32 h drug light interval showed no skin photosensitization. This drug 
displayed intense fluorescent signals in an in vivo imaging setup, confirming 
our earlier assertion. 
Overall, these studies push the boundaries for the search of effective 
NIR photodynamic agents and fluorescent probes for improved 
photodynamic response and fluorescence imaging in vivo. Our design and 
synthesis strategy would be useful to obtain functional NIR BODIPYs for the 
described applications. 
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Appendix 1 
General Methods 
Photophysical Properties 
Molar Extinction Coefficient. To measure the extinction coefficient, about 
1 mg of compounds 8-12 was dissolved in chloroform (50 ml). Serial 
dilutions were performed to yield different dye concentrations in the region 
of 10-7 – 10-6 M from the stock solution. The absorbance and absorption 
spectra measurements were taken using the Optics (CHEMUSB4-UV-
Fiber) spectrophotometer. A graph of absorbance (A) versus concentration 
(C) was plotted and the extinction coefficient was determined from Beer–
Lambert law. 
Determination of Fluorescence Quantum Yield. The fluorescence 
emission spectra of 39-43 using KFL-4 as a standard were recorded at 
25oC. Dilute solutions of all dyes (5 µM) were prepared to compare their 
fluorescence emission spectra after the excitation at 710 nm. The quantum 
yields were calculated following standard protocol.60, 97 Five serial dilutions 
were made with chloroform as a solvent, the absorbance (A) of these 
solutions were less than 0.1. The integrated fluorescence intensity (F) at 
each concentration was recorded after the excitation at 710 nm. A graph of 
F versus A was plotted to generate the gradient (G). The quantum yield was 
calculated using the equation: 
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ϕx = ϕstd 	 GxGstd 
ηx 
ηstd 
Where the subscripts std and x denote standard and test respectively,  is 
the fluorescence quantum yield, G the gradient from the plot of integrated 
fluorescence intensity vs. absorbance and  the refractive index of the 
solvent. The quantum yield of KFL-4 was 0.56 in chloroform.  
 
Detection of singlet oxygen by DPBF oxidation. A singlet oxygen 
generation experiment was set up, using a water filter and a 60 W halogen 
lamp at 0.5 mW/cm2. Sample solutions were prepared in small test tubes 
containing a magnetic stir bar. The tubes contained 90 µM DPBF and 5 µM 
dye solution in THF (2 ml). The dyes used were KFL-4, CMP, and dyes 39-
43. The solutions were stirred in the dark for two minutes and the 
absorbance measured in a quartz cuvette on Spectra Max2 
spectrophotometer (Molecular Devices). Stirring of the solutions continued 
under light irradiation for 18 min and the absorbance was measured at 
interval of 2 min. 
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Appendix 2 
1H-NMR Spectra of Compounds 
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1D NOESY and ROESY NMR 
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Appendix 3 
Crystallographic Data 
BDP635 single crystals were grown by slow evaporation from 
dichloromethane to obtain black plates. X- ray crystal structure was 
determined by Douglas R. Powell at the University of Oklahoma and thanks 
to the University of Oklahoma and the National Science Foundation (grant 
CHE-0130835) for funds to purchase the X-ray instrument and computers. 
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